Page last updated: 2024-11-05

galactose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

galactopyranose : The pyranose form of galactose. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

beta-D-galactose : A D-galactopyranose having beta-configuration at the anomeric centre. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

beta-D-galactoside : Any D-galactoside having beta-configuration at its anomeric centre. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

alpha-D-galactoside : Any D-galactoside having alpha-configuration at its anomeric centre. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

aldohexose : A hexose with a (potential) aldehyde group at one end. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6036
CHEMBL ID195923
CHEBI ID4139
CHEBI ID28260
CHEBI ID12936
SCHEMBL ID38935
MeSH IDM0008938
PubMed CID439353
CHEMBL ID300520
CHEBI ID27667
SCHEMBL ID42465
MeSH IDM0008938
PubMed CID439357
CHEMBL ID1233058
CHEBI ID28061
SCHEMBL ID18314
MeSH IDM0008938
PubMed CID24749
CHEMBL ID1206211
CHEBI ID33917
SCHEMBL ID1812
MeSH IDM0008938

Synonyms (215)

Synonym
O_FULL_10000000000000_GS_94
10257-28-0
d galactose
GAL ,
MLS001335983
smr000857326
MLS001335984
galactose, pure
galactose, d- (8ci)
galactopyranoside
d-galactose (9ci)
ai3-18440
galactopyranose
brain sugar
CHEBI:4139 ,
d-galactopyranose ,
GALACTOSE ,
C00124
d-galactose ,
NCGC00166082-01
CHEMBL195923
G0008
(3r,4s,5r,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
einecs 233-595-2
nsc 8102
HMS2230N07
S3849
EPITOPE ID:141794
G-1701
SCHEMBL38935
d-gal
d-galactopyranoside
WQZGKKKJIJFFOK-SVZMEOIVSA-N
bdbm228805
(3r,4s,5r,6r)-6-methyloltetrahydropyran-2,3,4,5-tetrol
galactose; d-galactopyranose; d(+)-galactose; gsk 620104e; allopurinol related
AKOS030573864
CS-0204480
mfcd00006969
(3r,4s,5r,6r)-6-(hydroxymethyl)tetrahydro-2h-pyran-2,3,4,5-tetraol
40825-89-6
AS-46931
Q27106307
DTXSID001015860 ,
CCG-266426
F10950
d-galactose 1000 microg/ml in methanol:water
EN300-135967
d-galacto-hexose
chebi:28260
dtxcid601437050
galacto-hexose
galaktose
chebi:12936
Z1665647488
wurcs=2.0/1,1,0/(a2112h-1x_1-5)/1/
dtxcid903088
bdbm50077229
beta-d-galactosides ,
CHEBI:27667 ,
beta-d-gal
gal-beta
beta-d-galactose
beta-d-galactoside
beta-d-galactopyranose
C00962
cerebrose
6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetraol
7296-64-2
1AXZ
1OKO
1PUM
1GCA
1UGW
9ABP
(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetraol
(2r,3r,4s,5r,6r)-6-(hydroxymethyl)tetrahydro-2h-pyran-2,3,4,5-tetraol
CHEMBL300520 ,
(2r,3r,4s,5r,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
sarcotoxin iib
105430-43-1
galactopyranose, beta-d-
beta-galactose
rq6k52j67a ,
unii-rq6k52j67a
(2r,3r,4s,5r,6r)-6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol
EPITOPE ID:136044
galactosidase, .beta.-
galactitol,1,5-anhydro-1-c-phenyl-
d-galactose .beta.-form [mi]
.beta.-galactose
.beta.-d-galactose
SCHEMBL42465
betagal
beta-gal
WQZGKKKJIJFFOK-FPRJBGLDSA-N
.beta.-d-galactopyranose
AKOS030242895
beta-delta-galactoside
beta-delta-galactosides
beta d-galactose
b-galactose
delta-galactose
b-d-galactose
Q27103248
DTXSID001015884 ,
i(2)-d-galactose
dtxcid701474039
d-galactose beta-form
wurcs=2.0/1,1,0/(a2112h-1b_1-5)/1/
alpha-d-gal
CHEBI:28061 ,
gal-alpha
CHEMBL1233058
D04291
galactose (nf)
alpha d-galactose
(+)-galactose
C00984
ALPHA-D-GALACTOSE ,
alpha-d-galactopyranose
3646-73-9
inchi=1/c6h12o6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11h,1h2/t2-,3+,4+,5-,6+/m1/s
5ABP ,
8ABP ,
BMSE000013
(2s,3r,4s,5r,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
AKOS006283213
BMSE001006
unii-7iof6h4h77
7iof6h4h77 ,
galactose [usan:nf]
alpha-d-galactoside
EPITOPE ID:136906
gtpl4646
d-galactose .alpha.-form [mi]
bdbm50423644
WQZGKKKJIJFFOK-PHYPRBDBSA-N
alphagal
SCHEMBL18314
DTXSID90189974 ,
alpha-galactose
alpha-d-galactose; d-galactose; galactose; alpha d-galactose
Q181381
i+/--d-galactose
dtxcid50112465
d-galactose alpha-form
wurcs=2.0/1,1,0/(a2112h-1a_1-5)/1/
nsc-2573
nsc2573
altrose, d-
galactose, d-
nsc26247
nsc224293
SGCUT00120
d-(+) glucose
nsc83659
25191-16-6
nsc-83659
glucose (d)
wln: t6otj bq cq dq eq f1q -d,glu
NSC406891 ,
1990-29-0
TO_000009
F25D46D2-AF25-42CF-BA85-09669814B5DC
2,3,4,5,6-pentahydroxyhexanal
FT-0695043
FT-0653883
FT-0695032
FT-0695033
FT-0694936
FT-0668995
FT-0695771
AKOS009156817
hexoses ,
CHEMBL1206211
FT-0624362
FT-0633931
FT-0625621
FT-0627599
FT-0633956
FT-0637777
FT-0622900
FT-0627823
FT-0627590
FT-0645150
SCHEMBL1812
CHEBI:33917 ,
aldohexose
aldohexoses ,
hexose #
HMS3651M12
glucose, l-, [1-14c]
2,3,4,5,6-pentahy-droxyhexanal
FT-0695815
SY069569
4,4-methylenebis(2,6-diisopropylaniline)
CS-0266345
93780-23-5
STL185552
2-(1h-benzimidazol-2-ylthio)propanoicacid
SB44748
SB45026
SB46961
SB45528
SB40630
SB44733
SB44882
SB45632
SB44794
SB44854
SB45057
SY073251
alpha-d-glucopyranose-1,6-13c2
EN300-49119

Research Excerpts

Overview

D-Galactose is an abundant carbohydrate monomer in nature and widely exists in macroalgae, plants, and dairy wastes. Galactosemia is an inborn disorder of carbohydrate metabolism characterized by the inability to metabolize galactose.

ExcerptReferenceRelevance
"D-Galactose is an abundant carbohydrate monomer in nature and widely exists in macroalgae, plants, and dairy wastes. "( An overview of D-galactose utilization through microbial fermentation and enzyme-catalyzed conversion.
Chen, Q; Guang, C; Mu, W; Wu, H; Xu, W; Zhang, W, 2021
)
1.68
"Galactose is a major component of cell wall polymers, glycolipids and glycoproteins; therefore, it becomes surprising that exogenous addition of galactose leads to drastic root phenotypes including cessation of primary root growth and induction of lateral root formation."( Overexpression of UDP-sugar pyrophosphorylase leads to higher sensitivity towards galactose, providing new insights into the mechanisms of galactose toxicity in plants.
Althammer, M; Blöchl, C; Herburger, K; Huber, CG; Regl, C; Tenhaken, R; Voglas, E, 2022
)
1.67
"D-galactose is a hexose sugar present mainly in hemicellulose and pectin in plant biomass."( Detailed analysis of the D-galactose catabolic pathways in Aspergillus niger reveals complexity at both metabolic and regulatory level.
Chroumpi, T; de Vries, RP; Garrigues, S; Grigoriev, IV; Kun, RS; Lipzen, A; Mäkelä, MR; Martínez-Reyes, N; Ng, V; Peng, M; Tejomurthula, S; Zhang, Y, 2022
)
1.58
"Galactose is an abundant and essential sugar used for the biosynthesis of many macromolecules in different organisms, including plants. "( Hexose transporter SWEET5 confers galactose sensitivity to Arabidopsis pollen germination via a galactokinase.
Chen, LQ; Li, Y; Wang, J; Yu, YC, 2022
)
2.44
"D-galactose (D-gal) is a reducing sugar widely distributed in food. "( SRT1720 plays a role in oxidative stress and the senescence of human trophoblast HTR8/SVneo cells induced by D-galactose through the SIRT1/FOXO3a/ROS signalling pathway.
Chen, B; Chu, J; Ma, T; Niu, Y; Xu, L; Yin, L; Zheng, X, 2022
)
1.65
"Galactose is a sugar abundant in root cell walls of Arabidopsis."( Galactose induces formation of cell wall stubs and cell death in Arabidopsis roots.
Althammer, M; Foissner, I; Höftberger, M; Tenhaken, R, 2022
)
2.89
"Galactosemia is an inborn disorder of carbohydrate metabolism characterized by the inability to metabolize galactose, a sugar contained in milk (the main source of nourishment for infants), and convert it into glucose, the sugar used by the body as the primary source of energy. "( Galactosemia: Biochemistry, Molecular Genetics, Newborn Screening, and Treatment.
Parenti, G; Rossi, A; Ruoppolo, M; Sacchettini, R; Succoio, M, 2022
)
3.61
"Galactose is a secondary fermentable sugar that requires specific regulatory and structural genes for its assimilation, which are under catabolite repression by glucose. "( Long-Term Adaptation to Galactose as a Sole Carbon Source Selects for Mutations Outside the Canonical GAL Pathway.
Buskirk, SW; Conboy, A; Lang, GI; Marad, DA; Martínez, AA, 2023
)
2.66
"Galactosemia is an inborn metabolic disorder caused by a deficient activity in one of the enzymes involved in the metabolism of galactose. "( The Importance of Neonatal Screening for Galactosemia.
Achim, AC; Badiu Tișa, I; Cozma-Petruț, A, 2022
)
2.43
"Galactose is a monosaccharide that can be naturally found in furanose configuration in plant and bacterial polysaccharides."( Ring-Size Memory of Galactose-Containing MS/MS Fragments: Application to the Detection of Galactofuranose in Oligosaccharides and Their Sequencing.
Compagnon, I; Ferrières, V; Legentil, L; Moge, B; Ollivier, S; Rogniaux, H; Ropartz, D; Yeni, O, 2023
)
1.96
"Galactosemia is an inborn error of carbohydrate metabolism caused by deficient activity of any of the galactose metabolising enzymes."( Pathophysiology and targets for treatment in hereditary galactosemia: A systematic review of animal and cellular models.
Berry, GT; Bierau, J; Coelho, AI; Haskovic, M; Rubio-Gozalbo, ME; Steinbusch, LKM; Vanoevelen, JM; Villamor-Martinez, E; Zimmermann, LJI, 2020
)
1.53
"The galactose-based polymer is a promising drug delivery material. "( Galactose-based polymer-containing phenylboronic acid as carriers for insulin delivery.
He, D; Li, Y; Song, B; Wang, P; Wu, J; Xia, Z; Zhong, Y, 2020
)
2.56
"Galactosemia is a rare autosomal recessive genetic disorder that causes impaired metabolism of the carbohydrate galactose. "( Two Lithuanian Cases of Classical Galactosemia with a Literature Review: A Novel
Dženkaitis, M; Kučinskienė, R; Labanauskas, L; Rokaitė, R; Traberg, R, 2020
)
2.28
"D-galactose (D-gal) is a carbohydrate widely distributed in regular diets. "( Oral administration of D-galactose increases brain tricarboxylic acid cycle enzymes activities in Wistar rats.
Behenck Medeiros, E; Bellettini-Santos, T; Braga Brandão, A; Budni, J; Casagrande Zabot, G; da Silva, S; de Oliveira, J; Lima Garcez, M; Mina, F; Quevedo, J; Scaini, G; Streck, EL, 2021
)
1.65
"Galactose is an essential carbohydrate for cellular metabolism, as it contributes to energy production and storage in several human tissues while also being a precursor for glycosylation. "( Galactose in human metabolism, glycosylation and congenital metabolic diseases: Time for a closer look.
Conte, F; Lefeber, DJ; van Buuringen, N; Voermans, NC, 2021
)
3.51
"d-galactose (d-gal) is a reducing sugar that widely distributed in foodstuffs, and studies show that d-gal could promote cataract formation by damaging nature lens epithelial cells (LECs)."( d-galactose induces premature senescence of lens epithelial cells by disturbing autophagy flux and mitochondrial functions.
Huang, W; Li, S; Li, Y; Ma, L; Niu, H; Wei, Z; Xin, G; Xing, Z; Xu, Y; Zeng, Z, 2018
)
1.76
"Galactose is an abundant monosaccharide found exclusively in mammals as galactopyranose (Gal p), the six-membered ring form of this sugar. "( Steric Control of the Rate-Limiting Step of UDP-Galactopyranose Mutase.
Cossio-Pérez, R; Da Fonseca, I; Kizjakina, K; Pierdominici-Sottile, G; Sobrado, P; Tanner, JJ, 2018
)
1.92
"Galactosemia is a metabolic disorder that affects the appropriate metabolism of β-D-galactose. "( The prevalence of GALM mutations that cause galactosemia: A database of functionally evaluated variants.
Arai-Ichinoi, N; Iwasawa, S; Kikuchi, A; Kure, S; Sakamoto, O; Tamiya, G; Wada, Y, 2019
)
2.22
"d-Galactose (D-Gal) is a sugar, which administered to mammals can induce cognitive deficits."( Administration of protocatechuic acid affects memory and restores hippocampal and cortical serotonin turnover in rat model of oral D-galactose-induced memory impairment.
Blecharz-Klin, K; Joniec-Maciejak, I; Krzysztoforska, K; Mirowska-Guzel, D; Piechal, A; Pyrzanowska, J; Widy-Tyszkiewicz, E, 2019
)
1.28
"Galactose was shown to be an effective inducer of catabolite repression in OMZ175, but not in the EII(Gal) -deficient strain."( A galactose-specific sugar: phosphotransferase permease is prevalent in the non-core genome of Streptococcus mutans.
Burne, RA; Stanhope, MJ; Xue, P; Zeng, L, 2013
)
1.83
"Galactosemia is an autosomal recessive disorder with a wide range of clinical abnormalities. "( Impaired NADPH oxidase activity in peripheral blood lymphocytes of galactosemia patients.
Al-Essa, M; Al-Qabandi, W; Dhaunsi, GS; Khan, I, 2013
)
2.07
"Galactosemia is an inborn error of galactose metabolism that occurs mainly as the outcome of galactose-1-phosphate uridyltransferase (GALT) deficiency. "( Galactose oxidation using (13)C in healthy and galactosemic children.
Ciampo, LA; Ferrioli, E; Junior, JS; Pfrimer, K; Porta, G; Resende-Campanholi, DR, 2015
)
3.3
"Galactose is a common composing monosaccharide in glycoconjugates."( Phylogeny, structure, function, biosynthesis and evolution of sulfated galactose-containing glycans.
Pomin, VH, 2016
)
1.39
"d-Galactose (d-gal) is a reducing sugar that can be used to mimic the characteristics of aging in rodents; however, the effects of d-gal administration by oral route are not clear. "( Oral administration of d-galactose induces cognitive impairments and oxidative damage in rats.
Bellettini-Santos, T; Budni, J; da Silva, S; de Medeiros, J; Garcez, ML; Mina, F; Pacheco, R; Quevedo, J; Steckert, AV; Valvassori, Sda S; Voss, BC, 2016
)
1.46
"The galactosemias are a family of autosomal recessive genetic disorders resulting from impaired function of the Leloir pathway of galactose metabolism. "( Drosophila melanogaster Models of Galactosemia.
Daenzer, JM; Fridovich-Keil, JL, 2017
)
1.29
"D-galactose is a simple and natural compound that has mainly been exploited in prodrug strategies. "( D-galactose as a vector for prodrug design.
Curcio, A; Luongo, E; Melisi, D; Morelli, E; Rimoli, MG, 2011
)
1.81
"Galactose is a common monosaccharide that can be utilized by all living organisms via the activities of three main enzymes that make up the Leloir pathway: GalK, GalT, and GalE. "( Galactose metabolism plays a crucial role in biofilm formation by Bacillus subtilis.
Beauregard, PB; Chai, Y; Kolter, R; Losick, R; Vlamakis, H, 2012
)
3.26
"Galactosemia is a genetic disease with deficiency of galactose-1-uridyltransferase, resulting in the accumulation of galactose or galactose-1-phosphate in the blood and tissues. "( Inhibitor of apoptosis proteins and ovarian dysfunction in galactosemic rats.
Cheng, LY; Cheung, AL; Lai, KW; O, WS, 2003
)
2
"UDP-galactose mutase is a flavoenzyme that catalyzes the isomerization of UDP-galactopyranose into UDP-galactofuranose, a key step in the biosynthesis of important bacterial oligosaccharides. "( Synthesis and inhibition properties of conformational probes for the mutase-catalyzed UDP-galactopyranose/furanose interconversion.
Brondello, JM; Caravano, A; Mengin-Lecreulx, D; Sinaÿ, P; Vincent, SP, 2003
)
0.88
"Thus galactosemia seems to be a secondary "dual" CDG causing a processing as well as an assembly N-glycosylation defect."( Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia.
Barone, R; Fiumara, A; Garozzo, D; Jaeken, J; O'Brien, JF; Pavone, L; Perez, M; Sorge, G; Sturiale, L; Tortorelli, S; Zaffanello, M, 2005
)
1
"d-Galactose proved to be a very efficient galactosyl acceptor; thus, a relatively large amount of galactobioses was formed."( Production of prebiotic galacto-oligosaccharides from lactose using beta-galactosidases from Lactobacillus reuteri.
Haltrich, D; Kulbe, KD; Lorenz, W; Nguyen, TH; Splechtna, B; Steinböck, M, 2006
)
0.89
"Galactosemia is a secondary glycosylation disorder and hypoglycosylation of glycoproteins has a role in this dysfunction."( The endocrine system in treated patients with classical galactosemia.
Menheere, PP; Panis, B; Rubio-Gozalbo, ME; Spaapen, LJ; Zimmermann, LJ, 2006
)
1.3
"Galactose is thought to be a more appropriate carbohydrate source for the newborn."( Potential role of galactokinase in neonatal carbohydrate assimilation.
Kliegman, RM; Miettinen, EL; Morton, S, 1983
)
0.99
"D-galactose is a reducing sugar that can form advanced glycation endproducts (AGE) in vivo."( Advanced glycation in D-galactose induced mouse aging model.
Bao, M; Li, D; Li, YM; Song, X, 1999
)
1.17
"Galactosemia is a potentially fatal disease resulting from a deficiency of galactose-1-phosphate uridyl transferase. "( Determination of [(13)C]galactose enrichment in human plasma by gas chromatography/positive chemical ionization tandem mass spectrometry.
Blair, IA; Fenn, PT; Ning, C; Segal, S, 2000
)
2.06
"Galactose is an energy-providing nutrient and also a necessary basic substrate for the biosynthesis of many macromolecules in the body. "( Galactose metabolism and ovarian toxicity.
Hale, GE; Hughes, CL; Liu, G,
)
3.02
"Galactose was shown to be a more critical nutrient when cultures reached a high density."( Metabolic active-high density VERO cell cultures on microcarriers following apoptosis prevention by galactose/glutamine feeding.
Antoniazzi, MM; Arrózio, SJ; Ferreira, JM; Mendonça, RZ; Pereira, CA, 2002
)
1.25
"Galactose-1-phosphate is a competitive inhibitor of galactose while the inhibition for Mg-ATP2- is not a competitive one."( [Purification and mechanism of action of a plant galactokinase].
Foglietti, MJ; Percheron, F, 1976
)
0.98
"Galactose serves as a nonmetabolized, gratuitous inducer of alpha-galactosidase in strains lacking the genes for one or more of the Leloir pathway enzymes."( Genetic co-regulation of galactose and melibiose utilization in Saccharomyces.
Douglas, HC; Kew, OM, 1976
)
1.28
"Galactosemia is a disorder caused by a deficiency of any one of three possible enzymes involved in the metabolism of galactose: galactokinase, transferase or epimerase. "( Galactose and cataract.
Stambolian, D,
)
3.02
"Galactose oxidase is a fungal enzyme which is known to oxidize the C-6 hydroxymethyl of galactose to an aldehyde group. "( Re-examination of the products of the action of galactose oxidase. Evidence for the conversion of raffinose to 6''-carboxyraffinose.
Bhavanandan, VP; Kelleher, FM, 1986
)
1.97
"Galactose is a major nutrient in normal newborn infants and serves as a substrate for energy production and fuel storage and a regulator of carbohydrate assimilation. "( Perinatal galactose metabolism.
Kliegman, RM; Sparks, JW, 1985
)
2.11
"Galactose is a weak inducer of beta-galactosidase synthesis in wild-type Escherichia coli K-12, but it is more effective when the wild type has been preinduced with isopropyl-beta-d-thiogalactoside."( Role of lac genes in induction of beta-galactosidase synthesis by galactose.
Llanes, B; McFall, E, 1969
)
1.21
"6. Galactose 1-phosphate is a non-competitive inhibitor when either galactose or MgATP(2-) was the variable substrate."( Kinetic studies with liver galactokinase.
Ballard, FJ, 1966
)
0.76

Effects

D-galactose (GAL) has been used as an animal model for brain aging and antiaging studies. Galactose has been selected by evolutionary pressure to exert also a crucial structural role in macromolecules.

ExcerptReferenceRelevance
"Galactose has a high affinity for FSPF, and experimental data suggest that it could reduce its activity."( FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy.
Ammann, H; De Smet, E; Déziel, C; Quérin, S; Rioux, JP, 2009
)
1.3
"D-galactose-induced aging has become a hot topic, and extensive research is being conducted in this area."( Antioxidative potential of Lactobacillus sp. in ameliorating D-galactose-induced aging.
Alomar, SY; Alwasel, SH; Bhardwaj, K; Cruz-Martins, N; Dhanjal, DS; Kuča, K; Kumar, D; Kumar, H; Singh, R; Valko, M; Verma, R, 2022
)
1.52
"d-galactose (D-gal) has been used to develop an aging model of brain."( Ameliorative effect of lithium chloride against d-galactose induced behavioral and memory impairment, oxidative stress and alteration in serotonin function in rats.
Bilal, K; Imran, I; Samad, N; Zulfiqar, I, 2019
)
1.33
"High-galactose diets has more pronounced effects on metabolic factors and gut permeability than high-fructose diets."( Effects of High Intakes of Fructose and Galactose, with or without Added Fructooligosaccharides, on Metabolic Factors, Inflammation, and Gut Integrity in a Rat Model.
Collino, M; Dal Bello, F; Frank, J; Kruger, J; Landberg, R; Medana, C; Mhd Omar, NA; Michaelsson, K; Wolk, A; Zamaratskaia, G, 2021
)
1.34
"D-galactose (D-gal) has been used extensively to develop aging model."( D-galactose induced dysfunction in mice hippocampus and the possible antioxidant and neuromodulatory effects of selenium.
Hafeez, F; Imran, I; Samad, N, 2022
)
2
"Galactose has been shown to be beneficial in other CDG types with abnormal galactosylation. "( Galactose Supplementation in Patients With TMEM165-CDG Rescues the Glycosylation Defects.
Cassiman, D; Climer, L; Foulquier, F; Gadomski, T; Jaeken, J; Lupashin, V; Matthijs, G; Morava, E; Morelle, W; Potelle, S; Witters, P; Wong, S, 2017
)
3.34
"D-galactose (gal) has been reported to cause symptoms of ageing in rats, accompanied by liver and brain injuries."( Antioxidative, anti-inflammatory and anti-apoptotic effects of ellagic acid in liver and brain of rats treated by D-galactose.
Chen, F; Chen, P; Zhou, B, 2018
)
1.25
"D-galactose (D-gal) has been considered a senescent model which induces oxidative stress response resulting in memory dysfunction."( PQQ ameliorates D-galactose induced cognitive impairments by reducing glutamate neurotoxicity via the GSK-3β/Akt signaling pathway in mouse.
Mao, SS; Peng, Y; Qin, XF; Xu, D; Yao, ZW; Zhang, RJ; Zhou, XQ, 2018
)
1.37
"d-galactose has been frequently used in rodents to accelerate aging."( The Effects of Light and Moderate Intensity Exercise on the Femoral Bone and Cerebellum of d-Galactose-Exposed Rats.
Agustiningsih, D; Karima, N; Partadiredja, G; Sofro, ZM; Utami, KP, 2019
)
1.29
"Galactose has been selected by evolutionary pressure to exert also a crucial structural role in macromolecules."( Galactose metabolism and health.
Berry, GT; Coelho, AI; Rubio-Gozalbo, ME, 2015
)
2.58
"D-galactose injection has been shown to induce many changes in mice that represent accelerated aging. "( Gene Transcriptional and Metabolic Profile Changes in Mimetic Aging Mice Induced by D-Galactose.
Fu, JP; Ji, XF; Li, RH; Mu, CK; Song, WW; Wang, CL; Zhou, YY; Zhu, XJ, 2015
)
1.36
"d-galactose has been considered a senescent model for age-related neurodegenerative disease. "( Caffeine prevents d-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain.
Ali, T; Kim, MO; Ullah, F; Ullah, N, 2015
)
1.46
"D-galactose (GAL) has been used as an animal model for brain aging and antiaging studies. "( Carnosine and taurine treatments diminished brain oxidative stress and apoptosis in D-galactose aging model.
Aydın, AF; Betül-Kalaz, E; Çoban, J; Doğan-Ekici, I; Doğru-Abbasoğlu, S; Uysal, M, 2016
)
1.38
"D-galactose (D-gal) has been considered an artificial aging model which induces oxidative stress and inflammatory response resulting in memory and synaptic dysfunction."( Anthocyanins Reversed D-Galactose-Induced Oxidative Stress and Neuroinflammation Mediated Cognitive Impairment in Adult Rats.
Ali, T; Chung, JI; Kim, MO; Rehman, SU; Shah, SA, 2017
)
1.32
"The galactose network has been extensively studied at the unicellular level to broaden our understanding of the regulatory mechanisms governing galactose metabolism in multicellular organisms. "( Mathematical model of galactose regulation and metabolic consumption in yeast.
Khadra, A; Mackey, MC; Mitre, TM, 2016
)
1.31
"Galactose has a high affinity for FSPF, and experimental data suggest that it could reduce its activity."( FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy.
Ammann, H; De Smet, E; Déziel, C; Quérin, S; Rioux, JP, 2009
)
1.3
"Galactose moieties have been introduced on the uronic groups of alginates from different sources via an N-glycosidic bond, thus affecting the net charge on the polymer chain. "( Galactose-substituted alginate 2: conformational aspects.
Campa, C; Coslovi, A; Donati, I; Gamini, A; Paoletti, S; Skjåk-Braek, G; Vetere, A,
)
3.02
"Galactose has been used as a tool to modify gene activity in the giant puffs Balbiani ring 2 (BR2) and Balbiani ring 1 (BR1) on chromosome IV in the salivary glands of Chironomus tentans. "( Modulation of 75S RNA synthesis in the Balbiani rings of Chironomus tentans with galactose treatment.
Daneholt, B; Nelson, LG, 1981
)
1.93
"Galactose transport has only one natural substrate, D-galactose, and is encoded by the gene GAL2."( Sugar transport in Saccharomyces cerevisiae.
Lagunas, R, 1993
)
1.01
"Galactose cataracts have been associated with lens edema attributed to the osmotic stress of tissue polyol (galactitol) accumulation."( Taurine prevents galactose-induced cataracts.
Benford, SA; Malone, J; Malone, JI,
)
1.19
"Galactose has been used to induce changes in short-circuit current (delta Isc) across intestine."( Transport of galactose and sodium across lizard duodenum.
Badía, P; Bolaños, A; Gómez, T; Lorenzo, A, 1986
)
1.36
"The galactose binding has been estimated, with an affinity constant of 1.8.10(-7) M-1 in the absence of calcium."( Spectroscopical studies on the structural organization of the lectin discoidin I: analysis of sugar- and calcium-binding activities.
Cano, A; Pestaña, A; Valencia, A, 1989
)
0.76
"Galactose-fed chicks have been found to develop severe hyperosmolar dehydration. "( Galactose toxicity in the chick: hyperosmolality.
Malone, JI; Segal, S; Wells, HJ, 1971
)
3.13

Actions

D-Galactose promotes accumulation of reactive oxygen species and formation of advanced glycation end-products, ultimately resulting in oxidative stress. Galactosemia can also produce diabetic-like changes.

ExcerptReferenceRelevance
"D-galactose induced an increase in the SA-β-Gal positive cells, expression of p16 and p21 in vivo and in vitro."( Activation of α7nAChR by PNU282987 improves cognitive impairment through inhibiting oxidative stress and neuroinflammation in D-galactose induced aging via regulating α7nAChR/Nrf2/HO-1 signaling pathway.
Cao, C; Deng, Q; Li, S; Ma, R; Shi, L; Tian, J; Wang, W; Yu, C; Zhang, Y, 2023
)
1.67
"d-galactose (d-gal) can cause damages that resemble accelerated aging in mice."( Gallic acid attenuates thymic involution in the d-galactose induced accelerated aging mice.
Cao, JH; Chai, YR; Feng, YK; Guo, L; Li, JH; Sun, Y; Wang, LP; Wei, TT, 2020
)
1.37
"Galactose can inhibit the apoptosis and autophagy of pancreatic acinar cells induced by cerana, and its potential mechanism is to up-regulate FGF21 and Klotho, providing a new potential drug for the treatment of acute pancreatitis."( Galactose protects pancreatic acinar cells from cerulein induced damage by regulating FGF21 and Klotho.
Li, N; Wang, K; Yu, Z; Zhang, N, 2020
)
2.72
"Galactose and fructose increase the production of this protein while glucose prevents it, suggesting the involvement of catabolite repression."( Carbohydrate-controlled serine protease inhibitor (serpin) production in Bifidobacterium longum subsp. longum.
Bergonzelli, G; Bolten, CJ; Duboux, S; Golliard, M; Kleerebezem, M; Mercenier, A; Muller, JA, 2021
)
1.34
"D-Galactose (D-Gal) promotes accumulation of reactive oxygen species and formation of advanced glycation end-products, ultimately resulting in oxidative stress. "( Defective Central Immune Tolerance Induced by High-Dose D-Galactose Resembles Aging.
Du, HM; Liu, X; Wang, SL; Wang, YJ; Wu, SM; Yuan, Z; Zhu, XK, 2019
)
1.48
"D-galactose is known to cause oxidative stress and induce aging-related diseases. "( Effects of chronic treatment with diosgenin on bone loss in a D-galactose-induced aging rat model.
Amstislavskaya, TG; Chen, JH; Ding, SJ; Ho, YJ; Hung, YT; Kao, PF; Lan, HH; Liao, JM; Tikhonova, MA, 2014
)
1.36
"D-galactose was used to cause H9c2 cells senescence. "( [Study on protective effect of Panax notoginseng total saponins on H9c2 cells senescence against D-galactose].
Li, J; Liu, ZQ; Wang, JZ; Wang, T; Yang, L; Yuan, D; Zhang, CC, 2014
)
1.34
"Galactose caused an increase in fed-state hepatic glycogen content and a favourable shift in gut microbial populations."( Of the milk sugars, galactose, but not prebiotic galacto-oligosaccharide, improves insulin sensitivity in male Sprague-Dawley rats.
Cant, JP; Kim, JJ; Stahel, P; Xiao, C, 2017
)
1.5
"Galactose is known to enhance mitochondrial metabolism and could be an excellent model to study mitochondrial dysfunction in human primary myotubes."( Galactose enhances oxidative metabolism and reveals mitochondrial dysfunction in human primary muscle cells.
Aguer, C; Dent, R; Gambarotta, D; Harper, ME; Mailloux, RJ; McPherson, R; Moffat, C, 2011
)
2.53
"Galactose was found to cause a stimulatory effect on yield and productivity of arabinogalactan."( Production of polysaccharides by Silene vulgaris callus culture depending on carbohydrates of the medium.
Günter, EA; Ovodov, YS, 2003
)
1.04
"Galactosemia can also produce diabetic-like changes."( Consumption of a high-galactose diet induces diabetic-like changes in the inner ear.
Garrett, CG; McGuirt, WT; Pillsbury, HC; Prazma, J; Raynor, E; Robison, WG, 1995
)
1.33
"D-Galactose is used to suppress endogenous lysosomal beta-galactosidase activity, yielding a sixfold increase in sensitivity."( Differential suppression of background mammalian lysosomal beta-galactosidase increases the detection sensitivity of LacZ-marked leukemic cells.
Hagenbeek, A; Hendrikx, PJ; Martens, AC; Visser, JW, 1994
)
0.85
"Galactose is shown to enhance the intrinsic tryptophan fluorescence of GalR, the source of which is not explained by a change in decay times, but is due to an increase in the pre-exponential factor of the longest of the three fluorescence decay times."( The allosteric interaction between D-galactose and the Escherichia coli galactose repressor protein.
Brand, L; Brenowitz, M; Brown, MP; Shaikh, N, 1994
)
1.28
"D-galactose was unable to inhibit C-8 binding to either antibody, whereas ceramide was as efficient as Gal C.(ABSTRACT TRUNCATED AT 250 WORDS)"( Reactivity of two anti-galactosyl ceramide antibodies towards myelin basic protein.
McLaurin, J; Moscarello, MA, 1992
)
0.84
"galactose alone can cause any statistically significant changes in the red blood cell flux within superficial tumour regions."( Response of tumour red blood cell flux to hyperthermia and/or hyperglycaemia.
Kluge, M; Okunieff, P; Vaupel, P,
)
0.85

Treatment

D-galactose treatment increased testicular reactive oxygen species, thiobarbituric acid reactive substances, diene conjugates, protein carbonyls, advanced oxidation products of proteins and advanced glycation end products. Heat treatment (100 degrees C, 10 min) reduced anti-inflammatory action.

ExcerptReferenceRelevance
"D-galactose-treated mice showed pronounced fat deposition and impaired glucose and lipid homeostasis, along with increased oxidative damage and aging. "( Supplementation of Mussel Peptides Reduces aging Phenotype, Lipid Deposition and Oxidative Stress in D-Galactose-Induce Aging Mice.
Dong, Y; Song, S; Sun, S; Xu, Q; Zhou, Y; Zhu, S, 2017
)
1.39
"D-Galactose treatment increased testicular reactive oxygen species, thiobarbituric acid reactive substances, diene conjugates, protein carbonyls, advanced oxidation products of proteins and advanced glycation end products."( Carnosine prevents testicular oxidative stress and advanced glycation end product formation in D-galactose-induced aged rats.
Aydın, AF; Çoban, J; Doğan-Ekici, I; Doğru-Abbasoğlu, S; Koçak-Toker, N; Küçükgergin, C; Uysal, M, 2018
)
1.26
"D-galactose treatment, generally similar to NA, increased the lung pro-inflammatory status, as shown in the IL-6 and IL-1β levels and the expression of phospho-Jun and phospho-JNK, and the fibrotic status as shown in the hydroxyproline level compared to the vehicle. "( Fructo-oligosaccharide attenuates the production of pro-inflammatory cytokines and the activation of JNK/Jun pathway in the lungs of D-galactose-treated Balb/cJ mice.
Chan, ST; Chen, HL; Hong, MJ; Wu, TC; Yeh, SL, 2014
)
1.33
"D-galactose treatment mimicked the lung pro-inflammatory status as shown in the NA mice. "( Fructo-oligosaccharide attenuates the production of pro-inflammatory cytokines and the activation of JNK/Jun pathway in the lungs of D-galactose-treated Balb/cJ mice.
Chan, ST; Chen, HL; Hong, MJ; Wu, TC; Yeh, SL, 2014
)
1.33
"D-galactose treatment significantly decreased the number of nestin (a neural stem cell marker), Ki67 (a cell proliferation marker), and doublecortin (DCX, a differentiating neuroblast marker) positive cells compared to those in the control group."( Physical exercise ameliorates the reduction of neural stem cell, cell proliferation and neuroblast differentiation in senescent mice induced by D-galactose.
Choi, JH; Hwang, IK; Jung, HY; Kim, DW; Kim, JW; Kim, W; Nam, SM; Seong, JK; Won, MH; Yim, HS; Yoo, DY; Yoon, YS, 2014
)
1.16
"d-galactose-treated Wistar males had altered BOLD-response in the centers processing socially significant odor information and changed patterns of the functional connectivity."( Comparative study of perception and processing of socially or sexually significant odor information in male rats with normal or accelerated senescence using fMRI.
Akulov, AE; Amstislavskaya, TG; Ho, YJ; Kolosova, NG; Moshkin, MP; Romaschenko, AV; Tikhonova, MA, 2015
)
0.98
"Galactose or heat treatment (100 degrees C, 10 min) reduced anti-inflammatory action."( An anti-inflammatory lectin from Luetzelburgia auriculata seeds inhibits adhesion and rolling of leukocytes and modulates histamine and PGE2 action in acute inflammation models.
Alencar, NM; Bomfim, LR; Cavalcante, IJ; Cunha, FQ; Figueiredo, JG; Matos, MP; Nunes, JV; Oliveira, RS; Ramos, MV, 2010
)
1.08
"Galactose-treated mice also evinced alterations within their splenic white and red pulp."( Toxic effects of D-galactose on thymus and spleen that resemble aging.
Isobe, K; Ito, S; Nishio, N; Suzuki, H; Uddin, MN,
)
1.18
"D-galactose-(D-gal)-treated mouse, with cognitive impairment, has been used for neurotoxicity investigation and anti-neurotoxicity pharmacology research. "( NGF-Dependent activation of TrkA pathway: A mechanism for the neuroprotective effect of troxerutin in D-galactose-treated mice.
Hu, B; Lu, J; Wang, YJ; Wu, DM; Zhang, ZF; Zheng, YL, 2010
)
1.3
"Galactose-fed rats were treated orally with CA (10 and 50 mg/kg body weight) once a day for 2 weeks."( Inhibitory effects of chlorogenic acid on aldose reductase activity in vitro and cataractogenesis in galactose-fed rats.
Jo, K; Kim, CS; Kim, J; Kim, JS; Lee, YM; Sohn, E, 2011
)
1.31
"D-galactose-treated mice retained lipoproteins in the retinal pigment epithelial and Bruch's membrane to a greater extent than either PBS- or phenacylphiazolium bromide/D-galactose-treated mice at 24 and 72 hours after injection (P ≤ 0.04)."( Advanced glycation endproduct changes to Bruch's membrane promotes lipoprotein retention by lipoprotein lipase.
Cano, M; Dike, S; Fijalkowski, N; Handa, J; Kondo, N, 2011
)
0.93
"D-Galactose treatment increased reactive oxygen species and protein carbonyl levels (P<0.05), and reduced activity and protein production of glutathione peroxide, superoxide dismutase and catalase in mice brain (P<0.05)."( Anti-oxidative, anti-glycative and anti-apoptotic effects of oleanolic acid in brain of mice treated by D-galactose.
Tsai, SJ; Yin, MC, 2012
)
1.15
"Galactose oxidase treatment of immobilized 3-[(3-cholamidopropyl)dimethylamminio]-1-propanesulfonate-extractable glycoproteins of migrating and nonmigrating corneal epithelia resolved on sodium dodecylsulfate polyacrylamide gel electrophoresis was carried out."( Augmentation of galactose-specific glycoproteins during corneal epithelial migration in organ culture.
Asifa, A; Nikhat, A,
)
1.2
"D-Galactose treatment induced AGE-specific fluorescence in lens and RPE/choroid compared to buffer-treated controls. "( Ultrastructural aging of the RPE-Bruch's membrane-choriocapillaris complex in the D-galactose-treated mouse.
Handa, JT; Hjelmeland, LM; Ida, H; Ishibashi, K; Reiser, K, 2004
)
1.27
"Galactose treatment did not affect the onset of puberty as marked by the time of vaginal opening."( Dietary galactose inhibits GDF-9 mediated follicular development in the rat ovary.
Blas-Machado, U; Davis, VL; Foster, WG; Hughes, CL; Liu, G; Magoffin, DA; Shi, F; Yu, R, 2006
)
1.49
"D-galactose treated mice were similar to natural aging mouse in some aspects, but there was still big difference between them in immunology and behavior index. "( [A comparison study between D-galactose treated mice and natural aging mice].
He, N; Li, G; Liu, K; Wang, C, 2007
)
1.35
"Upon galactose treatment, resistant clones were less differentiated since they showed a heterogeneous monolayer organization accompanied by heterogeneous staining of cell-surface CEA and a high decrease (60-90%) of CEA release."( Multidrug-resistant phenotype influences the differentiation of a human colon carcinoma cell line.
Barra, Y; Mirrione, A; Rimet, O, 1999
)
0.76
"Treatment of D-galactose-stressed mice with the ethanolic extract of P."( Protective effects of Petroselinum crispum (Mill) Nyman ex A. W. Hill leaf extract on D-galactose-induced oxidative stress in mouse brain.
Patil, RB; Pillai, MM; Vora, SR, 2009
)
0.91
"With treatment, galactose in blood decreased from 8,892 ± 5,243 to 36.5 ± 49.3 μmol/l, galactose in urine from 31,820 ± 32,103 to 30.0 ± 36.1 μmol/mmol creatinine, galactitol in RBC from 1,584 ± 584 to 12.3 ± 9.4 μmol/l, and galactitol in urine from 11,724 ± 4,496 to 236 ± 116 μmol/mmol creatinine."( Features and outcome of galactokinase deficiency in children diagnosed by newborn screening.
Hennermann, JB; Klein, J; Mönch, E; Schadewaldt, P; Shin, YS; Vetter, B, 2011
)
0.7
"Mice treated with D-galactose to induce AGE formation in Bruch's membrane retain intravenously injected lipoproteins."( Advanced glycation endproduct changes to Bruch's membrane promotes lipoprotein retention by lipoprotein lipase.
Cano, M; Dike, S; Fijalkowski, N; Handa, J; Kondo, N, 2011
)
0.68
"Treatment of galactosemia requires a galactose-restricted diet. "( Galactose content of baby food meats: considerations for infants with galactosemia.
Gosnell, K; Gropper, SS; Weese, SJ; West, P, 2003
)
2.13
"Well-treated galactosemics retain a low level of red cell gal-1-P which increases after breaks of diet."( Galactose-1-phosphate in the pathophysiology of galactosemia.
Gitzelmann, R, 1995
)
2.09
"Treatment with galactose oxidase abolished the transfection ability of both the galactosylated histone H1 and asialo-orosomucoid."( Galactosylated histone-mediated gene transfer and expression.
Chen, J; Daichendt, KA; Stickles, RJ, 1994
)
0.63
"In untreated galactose-fed rats a 4-fold increase in the mean permeability surface area product (PA) to sucrose at the BRB was observed when the aqueous humor was not frozen during retinal dissection."( Permeability of the blood-retinal and blood-aqueous barriers in galactose-fed rats.
Caspers-Velu, LE; Kador, PF; Rapoport, SI; Wadhwani, KC, 1995
)
0.88
"The treatment of D-galactose dehydrogenase (24 mol lysine and 52 mol arginine per mol enzyme) with trypsin and subsequent peptide mapping showed 21, perhaps 22 peptides, indicating a structure comprising four identical subunits."( Subunit structure of D-galactose dehydrogenase from Pseudomonas saccharophila.
Kurz, G; Wengenmayer, F, 1975
)
0.88
"Treatment of galactose-intoxicated rats with ICI 128,436 restored to normal levels the elevated endoneurial sodium concentration, increased water content and interstitial fluid pressure characteristic of galactose neuropathy."( Edema and increased endoneurial sodium in galactose neuropathy. Reversal with an aldose reductase inhibitor.
Mizisin, AP; Myers, RR; Powell, HC, 1986
)
0.89
"Treatment of galactose, melibiose, and stachyose with galactose oxidase and catalase also resulted in the formation of the corresponding uronic acids."( Re-examination of the products of the action of galactose oxidase. Evidence for the conversion of raffinose to 6''-carboxyraffinose.
Bhavanandan, VP; Kelleher, FM, 1986
)
0.88

Toxicity

galactose-1-phosphate might cause a negative effect through inhibition of phosphoglucomutase. Only the galactsose blocked in alpha configuration provided a fine inhibition of 38-13 binding on BL Ramos cells.

ExcerptReferenceRelevance
"The toxic effect of Ricinus lectin RCA I, as estimated by the inhibition of [3H]leucine incorporation, was investigated on chick-embryo fibroblasts at different stages of development."( Changes in the sensitivity of chick fibroblasts to Ricinus lectin (RCA I) toxicity in relation to the stage of embryo development.
Aubery, M; Bernard, B; Bourrillon, R, 1979
)
0.26
" SDS-PAGE of the toxic fraction showed a single band with a Mr of about 150,000, and after dithiothreitol treatment, two bands with Mr of 100,000 and 50,000."( Detection of neutral sugars in purified type G botulinum progenitor toxin and the effects of some glycolytic enzymes on its molecular dissociation and oral toxicity.
Miyata, T; Nukina, M; Sakaguchi, G; Sakaguchi, S, 1991
)
0.28
" It was concluded that the 636 bispecific antibody was highly effective in targeting the toxic moiety of the molecule to CEA-expressing cells, and allowed exploitation of the additional ability of the B chain to facilitate cellular incorporation."( Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain.
Baldwin, RW; Charleston, A; Embleton, MJ; Pimm, MV; Robins, RA, 1991
)
0.28
" It is concluded that UDCA appears to be safe only in stages I to III and that prognostic stratification based on bile acid levels or on the histological stage of the disease should be an important aspect of controlled clinical trials."( Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III.
Bircher, J; Foelsch, UR; Lotterer, E; Raedsch, R; Stiehl, A, 1990
)
0.28
" Only the galactose blocked in alpha configuration provided a fine inhibition of 38-13 binding on BL Ramos cells and both alpha and beta-galactose allowed us to establish a clear distinction between the pathway entry of 38-13 IT in BL and non-BL cells; in close correlation with the 38-13 binding specificity the 38-13 IT cytotoxic effect in Ramos BL cells could also be prevented by alpha-Gal only, suggesting that this toxic action is probably mediated through the IT binding to Gb3 antigenic sites."( Comparison of inhibitory effect of galactose analogs on the binding and cytotoxicity of an anti-globotriaosylceramide monoclonal antibody coupled or not coupled to pokeweed antiviral protein.
Junqua, S; Le Pecq, JB; Mishal, Z; Wils, P, 1987
)
0.95
" It elicited powerful and specific toxic effects upon W3/25 antigen-expressing rat T-leukaemia cells."( Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates.
Brown, AN; Cumber, AJ; Forrester, JT; Foxwell, BM; Myers, CD; Ross, WC; Thorpe, PE, 1984
)
0.61
" The blocking of NC-mediated cytotoxicity was not due to a direct toxic action of the sugars on the effector cells."( Natural cytotoxic cells against solid tumors in mice: blocking of cytotoxicity by D-mannose.
Dien, P; Lattime, EC; Stutman, O; Wisun, RE, 1980
)
0.26
" It is concluded that while ricin and abrin share a common mechanism of action ricin is slightly less toxic than abrin."( Examination of the toxicity of several protein toxins of plant origin using bovine pulmonary endothelial cells.
Griffiths, GD; Lindsay, CD; Upshall, DG, 1994
)
0.29
" In 1 baboon, melibiose and arabinogalactan infusion delayed vascular rejection of a pig cardiac xenograft from 10 min to about 12 hr, at which time the baboon died from the toxic effects of the carbohydrate infusion."( Evidence that intravenously administered alpha-galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK15) and transplanted pig hearts.
Cooper, DK; Koren, E; Kosanke, S; Martin, M; Neethling, FA; Niekrasz, M; Oriol, R; Richards, SV; Ye, Y, 1994
)
0.29
"We used an in-vitro, inhibition of protein synthesis assay (PSI) to test a wide variety of drugs for possible therapeutic use against ricin, a toxic glycoprotein that causes death in animals by inhibiting protein synthesis."( Drugs that show protective effects from ricin toxicity in in vitro protein synthesis assays.
Pace, JG; Scovill, JP; Thompson, WL, 1995
)
0.29
" These lectins were toxic for Molt 4 cells in culture at concentrations in the pg/ml range, ML III being the most cytotoxic."( Modulation of mistletoe (Viscum album L.) lectins cytotoxicity by carbohydrates and serum glycoproteins.
Anton, R; Frantz, M; Jung, ML; Ribereau-Gayon, G, 2000
)
0.31
"A safe and novel agent, Gal-SOD has a protective effect against hepatic warm IR injury."( Inhibitory effects of safe and novel SOD derivatives, galactosylated-SOD, on hepatic warm ischemia/reperfusion injury in pigs.
Azuma, T; Fujioka, H; Furui, J; Hashida, M; Kanematsu, T; Mizoe, A; Nishikawa, M; Yuzawa, H,
)
0.13
" Retinoid-free cationic liposomes were more toxic than the other kinds (anionic and made only of PC) but were also the best delivery system for retinoic acid to induce specific cytotoxic effects on these tumor hepatoma cell lines."( Cytotoxic effect induced by retinoic acid loaded into galactosyl-sphingosine containing liposomes on human hepatoma cell lines.
Díaz, C; Gätjens-Boniche, O; Vargas, E, 2006
)
0.33
" The hypothesized toxic intermediate galactose-1-phosphate cannot be the sole cause of galactose related toxicity, but indications were found that galactose-1-phosphate might cause a negative effect through inhibition of phosphoglucomutase."( The roles of galactitol, galactose-1-phosphate, and phosphoglucomutase in galactose-induced toxicity in Saccharomyces cerevisiae.
Bro, C; de Jongh, WA; Nielsen, J; Olsson, L; Ostergaard, S; Regenberg, B, 2008
)
0.92
" Induced galactose toxicity is prevented by deletion of GAL4, which inhibits the transcriptional activation of genes involved in galactose metabolism and by deletion of the galactokinase (GAL1), indicating that galactose-1-phosphate, a phosphorylated intermediate of the Leloir pathway, is the toxic compound."( Overexpression of the aldose reductase GRE3 suppresses lithium-induced galactose toxicity in Saccharomyces cerevisiae.
Assis, LJ; Masuda, CA; Mendonça-Previato, L; Miranda, MN; Montero-Lomelí, M; Penha, LL; Previato, JO, 2008
)
1
" Yet, if this metabolic pathway is perturbed due to congenital deficiencies of the three associated enzymes, or an overwhelming presence of galactose, this monosaccharide which is abundantly present in milk and many non-dairy foodstuffs, will become highly toxic to humans and animals."( Galactose toxicity in animals.
Elsas, LJ; Lai, K; Wierenga, KJ, 2009
)
2
" The incidence of adverse events (AEs) associated with micafungin was 10."( Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
Aoki, G; Ishiyama, K; Kurokawa, T; Matano, S; Nakao, S; Sawazaki, A; Takami, A; Ueda, M; Yamaguchi, M; Yamauchi, H; Yamazaki, H; Yoshida, T, 2011
)
0.37
" The SC-Gal glycoconjugates were well tolerated; no adverse effects or mortality was observed during the 2-week observation period."( Acute oral safety study of sodium caseinate glycosylated via maillard reaction with galactose in rats.
Anadón, A; Ares, I; Castellano, V; Corzo-Martínez, M; Martínez, MA; Martínez-Larrañaga, MR; Moreno, FJ; Villamiel, M, 2014
)
0.63
" Nanoparticle functionalization with di-mannose (specifically carboxymethyl-α-D-mannopyranosyl-(1,2)-D-mannopyranoside), galactose (specifically carboxymethyl-β-galactoside), or glycolic acid induced no adverse effects after administration based on histopathological evaluation of liver, kidneys, and lungs."( Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles.
Boggiatto, PM; Goodman, JT; Hostetter, JM; Narasimhan, B; Pohl, NL; Roychoudhury, R; Vela-Ramirez, JE; Wannemuehler, MJ, 2015
)
0.62
"Ag-NPs coated with galactose and mannose were considerably less toxic to neuronal-like cells and hepatocytes compared to particles functionalized by glucose, ethylene glycol or citrate."( Carbohydrate functionalization of silver nanoparticles modulates cytotoxicity and cellular uptake.
Haase, A; Kennedy, DC; Lai, CH; Luch, A; Müller, L; Orts-Gil, G; Seeberger, PH, 2014
)
0.73
" The symptoms and medication score, levels of allergen-specific serum antibodies throughout the pollen season, and adverse effects with OIT were evaluated."( Safety and efficacy of a new regimen of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a prospective, randomized, open-label study.
Ejima, M; Kato, A; Kikkawa, S; Komune, S; Murakami, D; Saito, A; Sawatsubashi, M, 2015
)
0.42
" Importantly, no severe adverse effects were observed with OIT."( Safety and efficacy of a new regimen of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a prospective, randomized, open-label study.
Ejima, M; Kato, A; Kikkawa, S; Komune, S; Murakami, D; Saito, A; Sawatsubashi, M, 2015
)
0.42
"The new regimen of short-term OIT using the Cry j1-galactomannan conjugate for Japanese cedar pollinosis is effective, relatively safe and induces immune tolerance."( Safety and efficacy of a new regimen of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a prospective, randomized, open-label study.
Ejima, M; Kato, A; Kikkawa, S; Komune, S; Murakami, D; Saito, A; Sawatsubashi, M, 2015
)
0.42
" The Panel concluded that these galactomannans are safe in the present practices of use and concentration described in this safety assessment."( Safety Assessment of Galactomannans as Used in Cosmetics.
Andersen, FA; Belsito, DV; Bergfeld, WF; Heldreth, B; Hill, RA; Johnson, W; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.13
" Therefore, Delonix nanoparticles could be a safe and promising tool for ocular drug delivery."( Hydrophilic polymeric nanoparticles prepared from Delonix galactomannan with low cytotoxicity for ocular drug delivery.
Emery, FS; Lopez, RFV; Melo, SMG; Ogunjimi, AT; Vargas-Rechia, CG, 2017
)
0.46
" Therefore, development of an AIT that is safe and more convenient with a shorter regimen is needed."( Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a randomized controlled trial.
Kato, A; Komune, S; Murakami, D; Nakagawa, T; Omori, H; Saito, A; Sawatsubashi, M, 2017
)
0.46
" Collectively, these results suggest a possible species-specific toxic effect of sucrose on camel embryos, and that avoiding its use either in vitrification or warming solution is critical for establishing an effective protocol."( Successful pregnancies from vitrified embryos in the dromedary camel: Avoidance of a possible toxic effect of sucrose on embryos.
Billah, M; Herrid, M; Skidmore, JA, 2017
)
0.46
" Utilization of galactose requires a close interplay of the metabolic enzymes, as misregulation or malfunction of individual components can lead to the accumulation of toxic intermediate compounds."( Galactose metabolism and toxicity in Ustilago maydis.
Ammon, A; Dillner, B; Grün, N; Höll, C; Kämper, J; Klebl, F; Schuler, D; Ulrich, J; Voll, LM, 2018
)
2.27
" Acute toxicity tests showed a 40% lethality at a given rhein dose of 4000 mg/kg, and the LD50 of rhein was calculated by the bliss method to be greater than 2185."( Acute and subchronic toxicity studies of rhein in immature and d-galactose-induced aged mice and its potential hepatotoxicity mechanisms.
Chen, SY; Gao, Y; Huang, WY; Li, YQ; Meng, XL; Su, SY; Wang, P; Yang, D, 2022
)
0.96
" Histological examination revealed some morphological indicators of immune system activation and the absence of toxic effect on gastro-intestinal mucosa of animals at peroral administration of fungal glycoprotein fractions."( Proteins and polysaccharides from vegetative mycelium of medicinal basidiomycete Lentinus edodes display cytotoxicity towards human and animal cancer cell lines.
Fomin, A; Navolokin, N; Shirokov, A; Vetchinkina, E, 2022
)
0.72
" This study was designed to clarify the relationship between plasma membrane composition in terms of the differently linked sialic acid (Sia) content and cell susceptibility to toxic and misfolded Aβ-42 peptides."( Correlation between Sialylation Status and Cell Susceptibility to Amyloid Toxicity.
Bucciantini, M; Delfino, G; Leri, M; Nosi, D; Sgambati, E; Tani, A; Zecchi-Orlandini, S, 2022
)
0.72
" Preincubation of the effector cells, obtained from fresh whole blood, with mannose-6-phosphate, fructose-1-phosphate, or fructose-6-phosphate did not inhibit cytotoxicity, which indicated that these hexose phosphates are not nonspecifically toxic towards the effector lymphocytes."( Mannose 6-, fructose 1-, and fructose 6-phosphates inhibit human natural cell-mediated cytotoxicity.
Bretthauer, RK; Forbes, JT; Oeltmann, TN, 1981
)
0.26
" This was anticipated as a result of the osmotic effect of a large dose of relatively undigested sugar and was not considered a toxic effect."( 90-Day oral toxicity study of D-tagatose in rats.
Frankos, VH; Kruger, CL; Trimmer, GW; Whittaker, MH, 1999
)
0.3
" There were no adverse effects on reproductive performance noted in any treatment group."( Developmental toxicity study of D-tagatose in rats.
Frankos, VH; Kruger, CL; Schroeder, RE; Whittaker, MH, 1999
)
0.3
" Histopathology of the skin after application of developed NSD showed non-significant changes in skin anatomy indicating its safe nature."( Collagen loaded nano-sized surfactant based dispersion for topical application: formulation development, characterization and safety study.
Ahmad, FJ; Ahmad, I; Ahmad, MZ; Akhter, S; Khar, RK; Rizvi, MA; Shamim, M, 2014
)
0.4
"The rare sugar D-tagatose is a safe natural product used as a commercial food ingredient."( The rare sugar D-tagatose protects plants from downy mildews and is a safe fungicidal agrochemical.
Akimitsu, K; Ebihara, K; Fukumoto, T; Gomi, K; Ichimura, K; Izumori, K; Mochizuki, S; Ohara, T; Ohtani, K; Shigematsu, Y; Tajima, S; Tanaka, K; Yoshihara, A, 2020
)
0.56

Pharmacokinetics

Tolrestat was administered by gavage for 15 days to attain steady state. At six time intervals, rats were given access for 4 days to a 20% galactose diet, and killed. Clearance (CL) of ammonia and lidocaine were determined at three points during the perfusion using a one-compartment pharmacokinetic model.

ExcerptReferenceRelevance
" Diazepam elimination half-life (t1/2beta) and weight-corrected volume of distribution (Vd) were significantly larger in patients with cirrhosis (n = 9) than in controls (n = 4)."( Factors influencing diazepam pharmacokinetics: age, sex, and liver disease.
Greenblatt, DJ; Harmatz, JS; Shader, RI, 1978
)
0.26
"7 h), but mean maximum concentration Cmax was higher in patients (18."( Buspirone pharmacokinetics in patients with cirrhosis.
Dalhoff, K; Gammans, RE; Garred, P; Mayol, RF; Pfeffer, M; Placchi, M; Poulsen, HE, 1987
)
0.27
" A variable reduction in routine liver function tests was observed, possibly reflecting the influence of the different reserve synthetic capacity of the liver and, in the early postoperative phase, plasma half-life of liver products and blood loss or changes in plasma volume."( Evaluation of liver volume and liver function following hepatic resection in man.
Marchesini, G; Marra, A; Marrano, D; Melli, A; Pisi, E; Viti, G; Zoli, M, 1986
)
0.27
" The elimination half-life of femoxetine was within the normal limits in most of the patients."( Femoxetine clearance in patients with liver cirrhosis.
Hansen, BA; Keiding, S; Lund, J; Mengel, H, 1984
)
0.27
" After 28 days of immunization of rats with bovine serum albumin (BSA), approximately 90% of anti-BSA antibody was IgG; the circulating half-life of trace amounts of BSA antigen in immunized rats was 6 min, compared to 24 h in nonimmunized rats."( Carbohydrate-mediated clearance of immune complexes from the circulation. A role for galactose residues in the hepatic uptake of IgG-antigen complexes.
Baynes, JW; Day, JF; Thornburg, RW; Thorpe, SR, 1980
)
0.49
" Pharmacokinetic analysis revealed that their uptake rates were sufficiently large for selective drug targeting."( Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting.
Fujita, T; Hashida, M; Kamijo, A; Nishikawa, M; Sezaki, H; Takakura, Y, 1993
)
0.29
" This HPLC method has been successfully applied to the pharmacokinetic study of galactose in six patients with liver dysfunction."( Determination of galactose in human blood by high-performance liquid chromatography: comparison with an enzymatic method and application to the pharmacokinetic study of galactose in patients with liver dysfunction.
Hu, OY; Hu, TM; Tang, HS, 1995
)
0.86
" Tolrestat was administered by gavage (1 x 150 mg/kg, or 5, and 15 mg/kg/day for 15 days to attain steady state as estimated from the 53-h half-life of tolrestat determined in rat nerve); subsequently, at six time intervals, ranging from 4 to 59 days, rats were given access for 4 days to a 20% galactose diet, and killed."( Tolrestat pharmacokinetics in rat peripheral nerve.
Dvornik, D; Hicks, DR; Kraml, M; Millen, J,
)
0.31
" A significantly increased mean plasma peak concentration (40."( Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848).
Gross, V; Haag, K; Neis, W; Schölmerich, J; Treher, E; Wiegand, U, 1993
)
0.29
" In contrast, the two forms of IgG1 had similar kinetics in all the autoimmune-prone mice, whereas in BALB/c, there was a longer half-life (t1/2) for G0% IgG1."( Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice.
Apostolakos, P; Fournier, MJ; Newkirk, MM; Novick, J; Stevenson, MM, 1996
)
0.29
" The outflow patterns of [111In]Gal-BSAs at various inflow concentrations were simultaneously fitted to a one-organ pharmacokinetic model, by which we can characterize their binding to the cell surface and internalization processes separately."( Pharmacokinetic analysis of hepatic uptake of galactosylated bovine serum albumin in a perfused rat liver.
Hashida, M; Nishikawa, M; Ogawara, K; Takakura, Y, 1998
)
0.3
"In vivo receptor-mediated targeting of plasmid DNA to hepatocytes was achieved through optimizing the physicochemical and pharmacokinetic properties of a plasmid DNA/carrier complex."( Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties.
Hashida, M; Nishikawa, M; Takakura, Y; Takemura, S, 1998
)
0.3
"We introduced the pharmacokinetic method into the functional evaluation of xenogeneic extracorporeal liver perfusion as an artificial liver assist device, and examined the influence of xenogeneic humoral injury on the metabolic function of xenoperfused pig livers."( Evaluation of ammonia and lidocaine clearance, and galactose elimination capacity of xenoperfused pig livers using a pharmacokinetic analysis.
Ikai, I; Iwata, H; Kanazawa, A; Katura, N; Nishitai, R; Okabe, H; Satoh, S; Takeyama, O; Terajima, H; Uesugi, T; Yagi, T; Yamaoka, Y; Yoneyama, T, 1999
)
0.56
" Clearance (CL) of ammonia and lidocaine, and galactose elimination capacity (Vmax) were determined at three points during the perfusion using a one-compartment pharmacokinetic model."( Evaluation of ammonia and lidocaine clearance, and galactose elimination capacity of xenoperfused pig livers using a pharmacokinetic analysis.
Ikai, I; Iwata, H; Kanazawa, A; Katura, N; Nishitai, R; Okabe, H; Satoh, S; Takeyama, O; Terajima, H; Uesugi, T; Yagi, T; Yamaoka, Y; Yoneyama, T, 1999
)
0.81
" These results could be of great significance for PNA drug development, as they should allow modulation and fine-tuning of the pharmacokinetic profile of a drug lead."( Modulation of the pharmacokinetic properties of PNA: preparation of galactosyl, mannosyl, fucosyl, N-acetylgalactosaminyl, and N-acetylglucosaminyl derivatives of aminoethylglycine peptide nucleic acid monomers and their incorporation into PNA oligomers.
Dahl, O; Dolle, F; Hamzavi, R; Nielsen, PE; Tavitian, B,
)
0.13
"Ravuconazole is a new antifungal triazole with broad-spectrum activity and a long half-life in plasma."( Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Armstrong, D; Avila, NA; Bacher, J; Groll, AH; Hemmings, M; Lyman, CA; Mickiene, D; Peter, J; Petraitiene, R; Petraitis, V; Roussillon, K; Walsh, TJ, 2004
)
0.32
" Plasma and tissue samples were taken from each animal for AmpB pharmacokinetic analysis and tissue distribution determinations."( Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Bartlett, K; Risovic, V; Rosland, M; Sivak, O; Wasan, KM, 2007
)
0.34
"25h) in the body resulting in enhanced half-life of d4T (23."( Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes.
Dutta, T; Garg, M; Jain, NK, 2007
)
0.34
" In a single dose study, its pharmacokinetic profile was compared with that of ketorolac."( Galactosyl prodrug of ketorolac: synthesis, stability, and pharmacological and pharmacokinetic evaluations.
Abignente, E; Boatto, G; Calignano, A; Curcio, A; Gavini, E; La Rana, G; Melisi, D; Nieddu, M; Rimoli, MG; Russo, R; Sasso, O, 2009
)
0.35
" Bridging to humans using population pharmacokinetic (PK) data from a clinical trial in invasive aspergillosis was performed using Monte Carlo simulations."( Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
Bonate, P; Desai, A; Hope, WW; Kovanda, LL; Petraitiene, R; Petraitis, V; Walsh, TJ, 2016
)
0.43
" Furthermore, an inverse correlation between Gal exposure and estimated VWF half-life was observed in those patients with enhanced VWF clearance."( Increased galactose expression and enhanced clearance in patients with low von Willebrand factor.
Aguila, S; Brophy, TM; Byrne, M; Chion, A; Dalton, N; Di Paola, J; James, P; Jones, KL; Keenan, C; Lavin, M; Nolan, M; O'Connell, NM; O'Donnell, JS; O'Sullivan, JM; Patel, A; Patmore, S; Preston, RJS; Ryan, K; Trahan, GD, 2019
)
0.92
" Although pharmacokinetic profiles research is a viable approach to find the components being responsible for formula efficacy, the pharmacokinetics study of Tabson-2 decoction has not been elucidated yet."( Pharmacokinetics study of 16 active ingredients from Tabson-2 decoction in normal and d-galactose induced osteoporosis rats by liquid chromatography-tandem mass spectrometry.
Bu, R; Dong, X; Gao, P; Guo, X; Li, C; Li, N; Lu, Y; Ma, F; Tian, X; Tu, P; Xue, P, 2020
)
0.78
"Terminal sialylation determines the plasma half-life of von Willebrand factor (VWF)."( Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance.
Chion, A; Fazavana, J; Gardner, RA; Haberichter, S; McKinnon, TAJ; Monopoli, M; Moran, AB; O'Donnell, JS; O'Sullivan, JM; Sharma, J; Spencer, DIR; Ward, SE, 2022
)
0.95
"A pharmacokinetic model with two parallel absorption processes from two fractions has been derived for the percutaneous absorption of indomethacin."( A pharmacokinetic model for the percutaneous absorption of indomethacin and the prediction of drug disposition kinetics.
Atago, H; Ito, Y; Iwaki, M; Ogiso, T, 1989
)
0.28
"We studied the main pharmacokinetic parameters of ofloxacin when used free and niosomal forms of antibiotic to experimental white mice per os."( [Comparative study of pharmacokinetics of ofloxacin in a free and niosomal forms in experiments on white mice when administered per os].
Kovalev, DA; Kulichenko, AN; Liapustina, LV; Mikhaĭlova, ME; Pisarenko, SV; Siritsa, IuV, 2014
)
0.4
"A liquid crystalline (LC) system, composed of phosphatidylcholine, sorbitan monoleate, and tocopherol acetate, was investigated to understand the in vivo transformation after subcutaneous injection, coupled with the physicochemical and pharmacokinetic properties of the formulation."( The in vivo transformation and pharmacokinetic properties of a liquid crystalline drug delivery system.
Báez-Santos, YM; Lee, YN; Mun, EA; Otte, A; Park, K; Soh, BK, 2017
)
0.46
" As a pharmacodynamic marker, blood glucose levels were measured in diabetic rats."( An Industrial Procedure for Pharmacodynamic Improvement of Metformin HCl via Granulation with Its Paracellular Pathway Enhancer Using Factorial Experimental Design.
Al-Shoubki, AA; Donia, AA; Mady, OY, 2021
)
0.62
"Improving the drug permeation and consequently, the drug pharmacodynamic effect in addition to an excellent micromeritics property of the prepared drug granules showed the dual enhancement effect of the suggested industrial procedure."( An Industrial Procedure for Pharmacodynamic Improvement of Metformin HCl via Granulation with Its Paracellular Pathway Enhancer Using Factorial Experimental Design.
Al-Shoubki, AA; Donia, AA; Mady, OY, 2021
)
0.62

Compound-Compound Interactions

D-galactose (D-Gal) combined with aluminum trichloride (AlCl3) was used to study the effect of acteoside on the expression of neurotrophin-3.

ExcerptReferenceRelevance
" This study is aimed at discriminating between them, on the basis of the degree of acetylation and the acceptor sugars, by means of lectins combined with neuraminidase digestion and treatment with oxidizing and deacetylating agents."( Sialic acids in the chicken anterior lingual glands detected by lectins combined with enzymatic degradation and oxidizing agents.
Ceccarelli, P; Menghi, G; Scocco, P, 1995
)
0.29
" The lipophilization of the lysozyme combined with glycosylation is a promising method for potential industrial applications of the lysozyme due to the enhanced antimicrobial activity and the improved yield."( Improvement in the yield of lipophilized lysozyme by the combination with Maillard-type glycosylation.
Azakami, H; Kato, A; Liu, S, 2000
)
0.31
" Our study investigated the efficiency of routine testing of the Aspergillus galactomannan antigen (AGA) test in combination with chest CT scans for IPA diagnosis."( Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation.
Barbui, A; Busca, A; Falda, M; Libertucci, D; Limerutti, G; Locatelli, F; Serra, R, 2006
)
0.33
"The purpose of this study was to assess the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B (AmpB) following the administration of Abelcet and AmBisome alone and in combination with Caspofungin to rats infected with Aspergillus fumigatus."( Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Bartlett, K; Risovic, V; Rosland, M; Sivak, O; Wasan, KM, 2007
)
0.34
" Long-term OVX combined with D-gal injection serves as an ideal AD rodent model capable of mimicking pathological, neurochemical and behavioral alterations in AD."( Long-term D-galactose injection combined with ovariectomy serves as a new rodent model for Alzheimer's disease.
Ding, J; Han, Q; Hu, G; Hua, X; Lei, M; Xiao, M; Zhang, Y, 2007
)
0.72
" Preparative size-exclusion chromatography (SEC) and analytical SEC combined with three detectors were used to detect the TM1 and TM2 samples, confirming that the proteins were bonded to the polysaccharides."( Characterization of polysaccharide-protein complexes by size-exclusion chromatography combined with three detectors.
Tao, Y; Zhang, L, 2008
)
0.35
"We studied the antifungal activity of anidulafungin (AFG) in combination with voriconazole (VRC) against experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits and further explored the in vitro and in vivo correlations by using Bliss independence drug interaction analysis."( Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis.
Avila, NA; Bacher, J; Cotton, MP; Francesconi, A; Hope, WW; Hughes, JE; Kasai, M; Meletiadis, J; Mickiene, D; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Stergiopoulou, T; Walsh, TJ, 2009
)
0.35
"AD rat model was conducted by D-galactose intraperitoneal injection combined with lesions of nucleus basalis of Meynert (nbM)."( [Effects of D-galactose combined with lesions of nucleus basalis of Meynert on hippocampal long-term potentiation and synaptic morphology].
Gao, J; Hu, JQ; Lai, SL; Rao, Y; Wang, Q, 2002
)
0.96
"To understand the cytochemical properties of epididymal epithelial cells, the characteristics of glycoconjugates in the mouse epididymis were examined using the technique of lectin histochemistry combined with immunohistochemistry."( Cell- and region-specific expression of sugar chains in the mouse epididymal epithelium using lectin histochemistry combined with immunohistochemistry.
Fukui, T; Sawaguchi, A; Tajiri, S; Yoshinaga, K, 2012
)
0.38
"To study the effect of acteoside on the expression of neurotrophin-3 (NT-3) in brain tissues of subacute aging mice induced by D-galactose (D-Gal) combined with aluminum trichloride (AlCl3)."( [Acteoside enhances expression of neurotrophin-3 in brain tissues of subacute aging mice induced by D-galactose combined with aluminum trichloride].
Gao, L; He, Y; Huo, S; Peng, X; Yan, M, 2014
)
0.82
"Female Kunming mice were randomly divided into vehicle control group, D-Gal combined with AlCl3 group , vitamin E group, piracetam group and acteoside groups [30, 60, 120 mg/(kg."( [Acteoside enhances expression of neurotrophin-3 in brain tissues of subacute aging mice induced by D-galactose combined with aluminum trichloride].
Gao, L; He, Y; Huo, S; Peng, X; Yan, M, 2014
)
0.62
"OVX combined with injection of D-gal can serve as a good animal model simulating AD disease."( Pathologic changes and dysfunctions of astrocytes in the complex rat AD model of ovariectomy combined with D-galactose injection.
Liang, GB; Tao, YQ, 2014
)
0.61
" In conclusion, we have demonstrated that S-βGM in combination with LP protects epithelial barrier function by modulation of cytokine secretion, thus giving an additional value to this MOS as a potential symbiotic."( Salmosan, a β-galactomannan-rich product, in combination with Lactobacillus plantarum contributes to restore intestinal epithelial barrier function by modulation of cytokine production.
Brufau, MT; Campo-Sabariz, J; Carné, S; Ferrer, R; Martín-Venegas, R, 2017
)
0.46
"To investigate the protective effect of Panax notoginseng saponins combined with total flavonoids of epimedium on D-gal-induced senescence of H9c2 cells and explore its underlying mechanisms."( [Protective effect of total saponins of Panax notoginseng combined with total flavonoids of epimedium on D-galactose-incuced senescence of H9c2 cell].
Deng, LL; Li, J; Wang, T; Yuan, D; Zhang, CC; Zhou, ZY, 2017
)
0.67
" We undertook a meta-analysis of 13 studies involving 1513 patients to evaluate the utility of GM in combination with BDG or LFD for diagnosing IA."( The performance of galactomannan in combination with 1,3-β-D-glucan or aspergillus-lateral flow device for the diagnosis of invasive aspergillosis: Evidences from 13 studies.
Chen, G; Feng, J; Guo, Z; Huang, Y; Xie, S; Zhang, L; Zhou, J, 2019
)
0.51
"To investigate the value of serum galactomannan antigen (GM) testing combined with chest computed tomography (CT) as a noninvasive method for early diagnosis of invasive pulmonary aspergillosis (IPA) in patients with hematological malignancies with febrile neutropenia after antifungal drug treatment."( Utility of serum galactomannan antigen testing combined with chest computed tomography for early diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies with febrile neutropenia after antifungal drug treatment.
Cai, R; Guo, G; He, P; Wang, X; Zhang, M, 2019
)
0.51
"The purpose of our study was to evaluate the diagnostic value of serum galactomannan antigen (GM) testing combined with chest computed tomography (CT) of invasive pulmonary aspergillosis (IPA) in pediatric patients after hematopoietic stem cell transplantation."( The early diagnostic value of serum galactomannan antigen test combined with chest computed tomography for invasive pulmonary aspergillosis in pediatric patients after hematopoietic stem cell transplantation.
Fang, JP; Huang, K; Li, Y; Liao, XY; Qiu, KY; Xu, HG; Zhou, DH, 2019
)
0.51
" Furthermore, HBO combined with AOSC had a better effect than HBO or AOSC alone."( Acidic oligosaccharide sugar chain combined with hyperbaric oxygen delays D-galactose-induced brain senescence in mice via attenuating oxidative stress and neuroinflammation.
Long, Y; Mao, Y; Sun, S; Wang, G; Wang, X; Zhao, J; Zheng, X, 2022
)
0.95
" In conclusion, CGA in combination with EGCG ameliorated the gut alterations induced by aging, in part, through antioxidant and anti-inflammatory effects, along with its gut microbiota modulatory capacity."( Chlorogenic acid combined with epigallocatechin-3-gallate mitigates D-galactose-induced gut aging in mice.
Mackenzie, GG; Su, Z; Wei, R, 2023
)
1.14
"Lidocaine was shown to reduce cognitive impairment in rats with cognitive dysfunction through anti-inflammatory and antioxidative stress mechanisms in combination with CRMP2 antiphosphorylation."( Effect of lidocaine on cognitively impaired rats: Anti-inflammatory and antioxidant mechanisms in combination with CRMP2 antiphosphorylation.
Huang, L; Lin, X; Lin, Y; Zheng, X, 2023
)
0.91
"A study was made of the chronic effect of pesticides, within a wide range of doses, combined with whole-body gamma-irradiation, on the content of carbohydrate-containing proteins of rat liver."( [Changes in the content of carbohydrate-containing proteins in the liver of rats chronically exposed to pesticides combined with total gamma irradiation].
Shvedov, VL; Soroka, LP,
)
0.13
" The method takes advantage of sequential specific and nonspecific enzymatic treatment followed by selective purification and characterization of the glycopeptides using graphite powder microcolumns in combination with mass spectrometry."( Characterization of gel-separated glycoproteins using two-step proteolytic digestion combined with sequential microcolumns and mass spectrometry.
Højrup, P; Larsen, MR; Roepstorff, P, 2005
)
0.33
" Therefore in the present study, we hypothesized that bergamot oil, a psoralen-containing oil, would produce an optimized melanogenic effect in the clinical treatment of vitiligo when loaded within an elastic nanocarrier (spanlastics) and combined with PUVB for activation of psoralens."( Novel bergamot oil nanospanlastics combined with PUVB therapy as a clinically translatable approach for vitiligo treatment.
Fadel, M; Nasr, M; Sammour, O; Shaaban, M; Tawfik, AA, 2019
)
0.51

Bioavailability

The presence of glucose and galactose produced a significant impairment (up to 50%) in the rate of absorption of glycine. N-oleoyl-D-galactosamine was synthesized for fabricating biomimetic galactsose-modified nanoparticles (GNPs)

ExcerptReferenceRelevance
"Influence of the pH on the absorption rate of sugars by rat intestine in vivo has been revised by means of a technique for intestinal lumen perfusion with 1 minute absorption periods."( Effect of the pH on intestinal absorption of sugars in vivo.
Lluch, M; Ortiz, M; Ponz, F, 1979
)
0.26
"34 microL/min/cm, mean +/- SE, N = 4), calculated by dividing the absorption rate by the drug concentration, was significantly decreased (0."( Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs.
Awazu, S; Hayashi, M; Mizuma, T; Ohta, K, 1992
)
0.28
" In patients with glucose-galactose malabsorption the glucose absorption rate is as low as that of galactose."( Digestion and absorption rates of lactose, glucose, galactose, and fructose in three infants with congenital glucose-galactose malabsorption: perfusion studies.
Beyreiss, K; Hoepffner, W; Müller, F; Scheerschmidt, G, 1985
)
0.82
" Since intestinal sodium absorption was so enhanced by an actively transported sugar, fructose and galactose perfusion fluids were prepared, and it was found that fructose was less well absorbed than glucose or galactose: in general, the results with these sugars were consistent with the sodium-dependent active transport of galactose and the passive transport of fructose, unrelated to sodium transport."( Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions.
Ahmad, SZ; Hirschhorn, N; Kinzie, JL; Northrup, RS; Phillips, RA; Sachar, DB; Taylor, JO, 1968
)
0.46
" The presence of glucose and galactose produced a significant impairment (up to 50%) in the rate of absorption of glycine."( Impairment of glycine absorption by glucose and galactose in man.
Cook, GC, 1971
)
0.8
"The rate of absorption of glucose, galactose, and 3-0-methylglucose was studied in the rat's small intestine perfused in situ with isosmotic solutions containing these sugars and Na(2)SO(4) or K2SO(4)."( The effect of potassium on the intestinal transport of glucose.
Csáky, TZ; Ho, PM, 1966
)
0.52
" The bioavailability of alpha-1,6 and beta-1,3 linked galactose in foods is unknown."( Hidden sources of galactose in the environment.
Acosta, PB; Gross, KC, 1995
)
0.87
"The clinical efficacy of an aldose reductase (AR) inhibitor in diabetic polyneuropathy depends on its bioavailability at the site(s) of AR in peripheral nerves."( Tolrestat pharmacokinetics in rat peripheral nerve.
Dvornik, D; Hicks, DR; Kraml, M; Millen, J,
)
0.13
"Insulin-like growth factor I (IGF-I) bioavailability is reduced in liver cirrhosis, a condition frequently associated with malnutrition."( Effect of insulin-like growth factor I on in vivo intestinal absorption of D-galactose in cirrhotic rats.
Ainzúa, J; Castilla-Cortázar, I; García, M; Pascual, M; Picardi, A; Prieto, J; Quiroga, J; Tosar, A; Urdaneta, E, 1999
)
0.53
"Our objective was to investigate the effect of lactose on calcium bioavailability in humans by the use of a stable-strontium test under controlled metabolic conditions."( Lactose does not enhance calcium bioavailability in lactose-tolerant, healthy adults.
Bock, P; Drummer, C; Heer, M; Scheld, K; Stehle, P; Zittermann, A, 2000
)
0.31
"Pharmacokinetic parameters of strontium bioavailability were comparable for all 3 loads."( Lactose does not enhance calcium bioavailability in lactose-tolerant, healthy adults.
Bock, P; Drummer, C; Heer, M; Scheld, K; Stehle, P; Zittermann, A, 2000
)
0.31
"Lactose does not have a beneficial effect on calcium bioavailability in lactose-tolerant adults."( Lactose does not enhance calcium bioavailability in lactose-tolerant, healthy adults.
Bock, P; Drummer, C; Heer, M; Scheld, K; Stehle, P; Zittermann, A, 2000
)
0.31
" In addition, alterations in the bioavailability of numerous extralenticular growth factors has been reported and shown to result in various consequences."( Diabetes can alter the signal transduction pathways in the lens of rats.
Garcia-Castiñeiras, S; Kador, PF; Lou, MF; Zatechka, DS, 2003
)
0.32
"Novel glycosyl derivatives of dopamine and L-dopa (I-IV) are synthesized in order to overcome the problem of blood-brain barrier low permeability of dopamine and of low bioavailability of its precursor L-dopa."( Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies.
Boatto, G; Bonina, F; Calignano, A; De Caprariis, P; La Rana, G; Melisi, D; Nieddu, M; Puglia, C; Rimoli, MG, 2003
)
0.32
" Patients affected by LC often have a low bioavailability of the anabolic liver peptide insulin-like growth factor (IGF)-I."( Effect of insulin-like growth factor-I on nitrogen balance and intestinal galactose transport in rats with moderate liver cirrhosis.
Núñez, M; Santidrián, S; Urdaneta, E, 2003
)
0.55
" The aim of this study was to investigate whether increasing the viscosity of a topical aldose reductase inhibitor suspension increases the lenticular bioavailability of the inhibitor and whether such a formulation can arrest sugar cataract formation."( Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts.
Babb, T; Blessing, K; Kador, PF; Kompella, UB; Koushik, K; Randazzo, J; Takamura, Y; Zhu, W, 2007
)
0.34
" Aiming at improving its poor bioavailability of oral products, galactosylated liposomes were introduced in this work for silibinin delivery and targeting to the lectin receptors present on the hepatocytes."( Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin.
Dube, D; Goyal, AK; Khatri, K; Mishra, N; Vyas, SP, 2010
)
0.36
" The enzyme increased the amounts of free phenolic antioxidants in sour cherry pomace indicating that its hydrolyzing activity could potentially be applicable to improve the bioavailability of these compounds."( Characterization of a β-glucosidase with transgalactosylation capacity from the zygomycete Rhizomucor miehei.
Bencsik, O; Krisch, J; Papp, T; Takó, M; Vágvölgyi, C, 2012
)
0.38
" Finally, the bioavailability study in rabbits revealed that the absolute bioavailability of ondansetron hydrochloride was significantly increased from 28."( Thermally reversible xyloglucan gels as vehicles for nasal drug delivery.
Lohiya, G; Mahajan, HS; Nerkar, P; Tyagi, V,
)
0.13
", exhibits a wide range of pharmacological activity; however, its therapeutic use has been limited because of its low bioavailability following oral administration."( Curcumin/xanthan-galactomannan hydrogels: rheological analysis and biocompatibility.
Bresolin, TM; Da-Lozzo, EJ; Faraco, CD; Moledo, RC; Ortolani-Machado, CF; Silveira, JL, 2013
)
0.39
" The present contribution describes the safety and oral bioavailability of a novel water soluble formulation of curcumin, curcumagalactomannosides (CGM), when used as a dietary ingredient in selected food items."( Enhanced bioavailability and safety of curcumagalactomannosides as a dietary ingredient.
I M, K; Jeena, K; Kumar, D; Kuttan, R; Liju, VB; Maliakel, B, 2015
)
0.42
" The low molecular weight of MTrPP (155kDa; TrPP-13kDa) may increase its bioavailability than TrPP, thus MTrPP may possess higher antiulcer potential."( Modified pectic polysaccharide from turmeric (Curcuma longa): A potent dietary component against gastric ulcer.
Chandra Prakash, SV; Dharmesh, SM; Harsha, MR, 2016
)
0.43
"Black tea (BT) has been positively linked to improved redox status, while its efficacy is limited due to the low bioavailability of BT flavonoids."( Concomitant ingestion of lactic acid bacteria and black tea synergistically enhances flavonoid bioavailability and attenuates d-galactose-induced oxidative stress in mice via modulating glutathione antioxidant system.
Shah, NP; Zhao, D, 2016
)
0.64
"The main objective of this study was to develop novel BSA nanoparticles (BSA NPs) for improving the bioavailability of curcumin as an anticancer drug, and those BSA NPs were galactosylated for forming the curcumin-loaded galactosylated BSA nanoparticles (Gal-BSA-Cur NPs), thus enhancing their ability to target asialoglycoprotein receptor (ASGPR) overexpressed on hepatocellular carcinoma (HCC) cells."( Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration.
Hu, L; Huang, S; Huang, Y; Wan, J; Wang, D; Xia, Z; Xu, W; Zheng, G, 2018
)
0.48
" However, the application of Res was limited by its poor bioavailability and liver targeting."( Synthesis, cytotoxicity and liver targeting of 3-O-β-D-Galactosylated Resveratrol.
Chen, W; Hong, L; Qian, J; Wang, B; Zha, L; Zhang, C, 2019
)
0.51
"On the whole, Gal-Res increased cellular uptake to HepG2 cells, bioavailability and liver targeting, providing its future clinical application in the treatment of liver diseases."( Synthesis, cytotoxicity and liver targeting of 3-O-β-D-Galactosylated Resveratrol.
Chen, W; Hong, L; Qian, J; Wang, B; Zha, L; Zhang, C, 2019
)
0.51
" N-oleoyl-D-galactosamine was synthesized for fabricating biomimetic galactose-modified nanoparticles (GNPs) in an attempt to improve the oral bioavailability of IMT."( Oral delivery of imatinib through galactosylated polymeric nanoparticles to explore the contribution of a saccharide ligand to absorption.
Li, Y; Yang, B; Zhang, X, 2019
)
0.75
"All results demonstrated that Gal-BSA NPs could improve the intestinal absorption capacity and oral bioavailability of curcumin through the double absorption mechanisms of the clathrin-mediated endocytosis and the passive transport."( Evaluation of Intestinal Absorption Mechanism and Pharmacokinetics of Curcumin-Loaded Galactosylated Albumin Nanoparticles.
Deng, S; Huang, Y; Liu, Y; Luo, X; Pan, J; Wang, M; Xia, Z; Xu, W, 2019
)
0.51
" Owing to the existence of isomers, low bioavailability of some small molecule and interference of endogenous, the pharmacokinetics study of Tabson-2 decoction are more difficult than that of chemical drugs."( Pharmacokinetics study of 16 active ingredients from Tabson-2 decoction in normal and d-galactose induced osteoporosis rats by liquid chromatography-tandem mass spectrometry.
Bu, R; Dong, X; Gao, P; Guo, X; Li, C; Li, N; Lu, Y; Ma, F; Tian, X; Tu, P; Xue, P, 2020
)
0.78
"A novel self-emulsifying formulation of curcumin with fenugreek galactomannan hydrogel scaffold as a water-dispersible non-covalent curcumin-galactomannan molecular complex (curcumagalactomannosides, CGM) has shown better bioavailability than curcumin and can be used for the prevention and treatment of chronic diseases."( A novel bioavailable curcumin-galactomannan complex modulates the genes responsible for the development of chronic diseases in mice: A RNA sequence analysis.
Banik, K; Hegde, M; Khatoon, E; Kunnumakkara, AB; Naidu, VGM; Puppala, ER; Thakur, KK, 2021
)
0.62
" Methods adopted to increase the bioavailability of the drugs inside the cancer cells viz."( Structural modification and strategies for the enhanced doxorubicin drug delivery.
Alam Khan, S; Jawaid Akhtar, M, 2022
)
0.72
" Although small interfering RNA (siRNA) are potent to modulate the expression of hepcidin, their bioavailability remains a major issue."( Evaluation of liver specific ionizable lipid nanocarrier in the delivery of siRNA.
Bhatnagar, A; Prabhakar, N; Rana, S; Singh, S, 2022
)
0.72
" Echinacoside (ECH), a phenylethanoid glycoside isolated from Chinese herbal medicine, Cistanche salsa, can inhibit HCC progression; however, poor absorption and low bioavailability limit its biological applications."( Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery.
Ma, X; Mai, Z; Song, Y; Wang, G; Wang, M; Xia, W; Ye, Y; Zhang, M; Zhou, B, 2022
)
0.72
" On the other hand, the bioavailability of this structure was demonstrated with its high antioxidant activity (55."( Gene Expression, Structural Characterization, and Functional Properties of Exopolysaccharide Produced from Potential Probiotic Enterococcus faecalis NOC219 Strain.
Özdemir, N, 2023
)
0.91
" Our previous study found that acteoside showed high antiaging effect but its absorption rate was low."( Acteoside palliates d-galactose induced cognitive impairment by regulating intestinal homeostasis.
Huang, W; Li, M; Liu, X; Liu, Z; Lu, B; Quan, W; Xiao, X; Zhang, C; Zhu, M, 2023
)
1.22
"Influence of the pH on the absorption rate of sugars by rat intestine in vivo has been revised by means of a technique for intestinal lumen perfusion with 1 minute absorption periods."( Effect of the pH on intestinal absorption of sugars in vivo.
Lluch, M; Ortiz, M; Ponz, F, 1979
)
0.26
" Compound 1 at a concentration of 10 mM in the perfusate induced a twofold reduction of the absorption rate compared with the same concentration of 2 in saline."( Intestinal absorption of drugs. I: The influence of taurocholate on the absorption of dantrolene in the small intestine of the rat.
Crommelin, DJ; Poelma, FG; Tukker, JJ, 1989
)
0.28
" It was clarified that indomethacin was absorbed via both pathways, with rapid and slow absorption rate constants at the initial time stage, and via the latter pathway at the later period."( A pharmacokinetic model for the percutaneous absorption of indomethacin and the prediction of drug disposition kinetics.
Atago, H; Ito, Y; Iwaki, M; Ogiso, T, 1989
)
0.28
"D-Tagatose is a stereoisomer of D-fructose which is poorly absorbed in the small intestine and may, therefore, have potential as a reduced calorie bulk sweetener."( Human gastrointestinal tolerance to D-tagatose.
Astrup, A; Buemann, B; Toubro, S, 1999
)
0.3
"The lungs are useful for administration of macromolecules, which are poorly absorbed from the intestine."( Effect of additives on insulin absorption from intratracheally administered dry powders in rats.
Danjo, K; Iida, K; Okamoto, H; Todo, H, 2001
)
0.31
" There is no information on the mechanism of vitamin C transport across the intestinal barrier, a step that determines the bioavailability of vitamin C in humans."( Up-regulation and polarized expression of the sodium-ascorbic acid transporter SVCT1 in post-confluent differentiated CaCo-2 cells.
Bachem, M; Bustamante, ME; Cárcamo, JG; Grünert, A; Henríquez, EA; Kempe, S; Maulén, NP; Nualart, F; Schmid-Kotsas, A; Vera, JC, 2003
)
0.32
"Niosomes have been reported as a possible approach to improve the low corneal penetration and bioavailability characteristics shown by conventional ophthalmic vehicles."( Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Guinedi, AS; Hathout, RM; Mansour, S; Mortada, ND, 2005
)
0.33
"Intestinal membrane permeability is an important factor affecting the bioavailability of drugs."( Improved intestinal membrane permeability of hexose-quinoline derivatives via the hexose transporter, SGLT1.
Cook, TJ; Haga, M; Higashi, R; Maeda, T; Otake, K; Suzuki, H; Tamai, I; Yabuuchi, H, 2008
)
0.35
" The in vivo study revealed that the niosomal dispersion significantly improved the oral bioavailability of acyclovir in rabbits after a single oral dose of 40 mg kg(-1)."( Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.
Attia, IA; Donia, AM; El-Gizawy, SA; Fouda, MA, 2007
)
0.34
"The objectives of this research were to prepare celecoxib proniosomes and evaluate the influence of proniosomal formulation on the oral bioavailability of the drug in human volunteers."( In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration.
Nasr, M, 2010
)
0.36
" Poorly absorbed sweet tastants (TIM), which probably expose a greater length of gut to nutrients, result in delayed GLP-1 secretion but not in delayed GIP release."( Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans.
Bellon, M; Bound, MJ; Checklin, HL; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Young, RL; Zhao, BR, 2012
)
0.38
"The objective of the present study was to enhance solubility and bioavailability of itraconazole by a combined use of membrane emulsification and spray drying solidification technique."( Enhanced solubility and oral bioavailability of itraconazole by combining membrane emulsification and spray drying technique.
Choi, HG; Choi, YK; Kim, JO; Kim, JW; Marasini, N; Poudel, BK; Yang, KY; Yong, CS, 2012
)
0.38
" In vivo studies in rats indicated prolonged release and better oral bioavailability as compared to drug solution."( Design and development of multiple emulsion for enhancement of oral bioavailability of acyclovir.
Kumar, A; Paul, S; Sawant, K; Yedurkar, P, 2013
)
0.39
"In this study, niosome formulations were prepared and evaluated for their effects on improving the oral bioavailability of paclitaxel (PCT)."( Niosomes encapsulating paclitaxel for oral bioavailability enhancement: preparation, characterization, pharmacokinetics and biodistribution.
Onay-Besikci, A; Sezgin-Bayindir, Z; Vural, N; Yuksel, N, 2013
)
0.39
"The goal of this study was to demonstrate that MK-0364 solid dispersions can be developed as a means to increase the solubility and bioavailability of a poorly water-soluble drug, MK-0364."( Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364.
McKelvey, C; Moser, J; Rege, B; Sotthivirat, S; Xu, W; Zhang, D, 2013
)
0.39
" Granisetron suffers from reduced oral bioavailability (≈60%) due to hepatic metabolism."( Provesicular granisetron hydrochloride buccal formulations: in vitro evaluation and preliminary investigation of in vivo performance.
Ahmed, S; El-Latif Badawi, AA; El-Nabarawi, MA; El-Setouhy, DA, 2014
)
0.4
" The relative bioavailability of the optimized microspheres was compared with CTZ marketed product after oral administration on healthy human volunteers using a double blind, randomized, cross-over design."( Statistical optimization of controlled release microspheres containing cetirizine hydrochloride as a model for water soluble drugs.
Ahmed, OA; Ahmed, TA; Alsawahli, M; El-Helw, AR; El-Say, KM; Fahmy, UA; Hosny, KM; Kharshoum, RM, 2015
)
0.42
"Thiocolchicoside (TCC) is an effective therapeutic agent against the orthopaedic, traumatic and rheumatologic disorders but it suffer from the drawback of poor bioavailability due to extensive first pass metabolism and low permeability via the oral route."( Omega 3 fatty acid-enriched nanoemulsion of thiocolchicoside for transdermal delivery: formulation, characterization and absorption studies.
Ali, J; Baboota, S; Kumar, D, 2016
)
0.43
" On oral administration it undergoes extensive first pass metabolism, which outweighs its absorbance through gastrointestinal tract (GIT) and bioavailability of the drug in systemic circulation."( A novel vesicular transdermal delivery of nifedipine - preparation, characterization and in vitro/in-vivo evaluation.
Jain, K; Jakki, SL; Kuppusamy, G; Natarajan, J; Sood, S; Venkatachalam, S; Yasam, VR, 2016
)
0.43
"Microemulsions show significant promise for enhancing the oral bioavailability of biopharmaceutics classification system (BCS) class II drugs, but how about class III drugs remains unclear."( Improving oral bioavailability of metformin hydrochloride using water-in-oil microemulsions and analysis of phase behavior after dilution.
Cai, J; Hu, H; Huang, M; Li, Y; Song, J; Tian, N; Wang, Y; Wu, C; Xing, Q, 2014
)
0.4
" It is determined that bioavailability of ofloxacin in the niosomal form is 154% relative to the free form of the antibiotic."( [Comparative study of pharmacokinetics of ofloxacin in a free and niosomal forms in experiments on white mice when administered per os].
Kovalev, DA; Kulichenko, AN; Liapustina, LV; Mikhaĭlova, ME; Pisarenko, SV; Siritsa, IuV, 2014
)
0.4
"The developed MEs are a viable alternative to conventional eye drops, because of its ability to enhance bioavailability through its longer precorneal residence time and its ability to sustain the release of the drug."( Phase-transition W/O Microemulsions for Ocular Delivery: Evaluation of Antibacterial Activity in the Treatment of Bacterial Keratitis.
Bharti, SK; Kesavan, K, 2017
)
0.46
" Niosomes were utilized to allow for prolonged release of the drug, whereas the films were used to increase the drug's bioavailability via the sublingual route."( Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate.
Allam, A; Fetih, G, 2016
)
0.43
" Diacerein, a highly lipophilic antiosteoarthritic drug, was used as a model drug: it has variable oral bioavailability due to its poor aqueous solubility."( Development and in-vitro characterization of sorbitan monolaurate and poloxamer 184 based niosomes for oral delivery of diacerein.
Khan, MI; Madni, A; Peltonen, L, 2016
)
0.43
" However, lack of optimal bioavailability due to poor solubility and high toxicity at its therapeutic dose has hampered the clinical use of this anticancer drug."( Excipient selection and aerodynamic characterization of nebulized lipid-based nanoemulsion loaded with docetaxel for lung cancer treatment.
Abdul Rahman, MB; Abdulmalek, E; Ahmad, H; Asmawi, AA; Masarudin, MJ; Ngan, CL; Salim, N, 2019
)
0.51
"In this study, a nanoemulsion containing mebudipine [composed of ethyl oleate (oil phase), Tween 80 (T80), Span 80 (S80) (surfactants), polyethylene glycol 400, ethanol (cosurfactants), and deionized water] was prepared with the aim of improving its bioavailability for an effective antihypertensive therapy."( Use of artificial neural networks for analysis of the factors affecting particle size in mebudipine nanoemulsion.
Abbasi, S; Amani, A; Keyhanfar, F; Khani, S, 2019
)
0.51
" The performed cytotoxicity, cell apoptosis and pharmacokinetic experiments showed an enhanced bioavailability of BUF after encapsulation."( In situ phase transition of microemulsions for parenteral injection yielding lyotropic liquid crystalline carriers of the antitumor drug bufalin.
Angelova, A; Drechsler, M; Garamus, VM; Gong, Y; Li, N; Li, Y; Liu, J; Zou, A, 2019
)
0.51
" This arises the need for bioavailability enhancement and is achieved in the present case using niosomes as carrier system."( Bioavailability Enhancement of Polymyxin B With Novel Drug Delivery: Development and Optimization Using Quality-by-Design Approach.
Bhatt, N; Chauhan, MK, 2019
)
0.51
" Crystalline CoQ10 is lipophilic, water-insoluble, and poorly absorbed in the gut."( High-dose coenzyme Q10-loaded oleogels for oral therapeutic supplementation.
Lucangioli, S; Martinefski, MR; Masotta, NE; Rojas, AM; Tripodi, VP, 2019
)
0.51
" In conclusion, mucoadhesive olaminosomes succeeded in enhancing agomelatine bioavailability in rabbits' eyes confirming the development of a novel ocular nanocarrier for insoluble drugs."( Mucoadhesive olaminosomes: A novel prolonged release nanocarrier of agomelatine for the treatment of ocular hypertension.
Abd-Elsalam, WH; ElKasabgy, NA, 2019
)
0.51
"Solid self-emulsifying drug delivery system was an effective oral solid dosage form to improve the oral bioavailability of ivermectin."( Formulation Studies of Solid Self-Emulsifying Drug Delivery System of Ivermectin.
Ashara, KC; Lakkad, HA; Patel, VP, 2018
)
0.48
"The present study was focused on investigating niosomal gels loaded with cholinergic drug; pilocarpine HCl, for prolonged precorneal residence time and improved bioavailability for glaucoma treatment."( Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits.
Jain, N; Verma, A, 2020
)
0.56
"Food-grade proniosomes are a good vehicle for fortification of milk and yogurt without noticeable adverse changes in their organoleptic and physicochemical properties, thus increasing the potential for bioavailability of catechins in the gastrointestinal tract."( Formulation and characterization of catechin-loaded proniosomes for food fortification.
Laxmana Naik, N; Magdaline Eljeeva Emerald, F; Pushpadass, HA; Shruthi, PA; Surendra Nath, B, 2021
)
0.62
" The aim of this study was to investigate the impact of surfactant composition and surface charge of niosomes in enhancing oral bioavailability of repaglinide (REG) as a BCS II model drug."( The Impact of Surfactant Composition and Surface Charge of Niosomes on the Oral Absorption of Repaglinide as a BCS II Model Drug.
Bolourchian, N; Dadashzadeh, S; Haeri, A; Shahhosseni, S; Yaghoobian, M, 2020
)
0.56
" The developed nanoplatforms hence can be further used to formulate other drugs that suffer from low bioavailability due to extensive first-pass metabolism."( Simultaneous Optimization of Oral and Transdermal Nanovesicles for Bioavailability Enhancement of Ivabradine Hydrochloride.
Elsayed, I; Naguib, MJ; Teaima, MH, 2021
)
0.62

Dosage Studied

increased YHR076w gene dosage confers a growth advantage to both wild-type and YHR76w knockout strains on 2% ethanol or 2% galactose medium in a low O2 growth environment. Mice were administered a subcutaneous abdominal injection of D-galactose to induce the ageing model.

ExcerptRelevanceReference
" TMG resistance is probably a gal+ gene dosage effect."( The biochemical and genetic basis for high frequency thiomethyl galactoside resistance in lambda,lambdadg lysogens of Escherichia coli.
Elliott, RW; Raney, ME, 1978
)
0.26
" Conversely, other genes expressed in proportion to dosage cannot be identified if their products are toxic at elevated levels."( Dominant genetics using a yeast genomic library under the control of a strong inducible promoter.
Davis, RW; Elledge, SJ; Ramer, SW, 1992
)
0.28
" One half of CONT and RAD groups were dosed orally with enprostil, 5 micrograms/kg body weight, and the other half of the CONT and RAD groups were dosed with placebo."( Lack of protective effect of oral enprostil, a synthetic prostaglandin E2, on intestinal transport and morphology following abdominal irradiation in the rat.
Cheeseman, CI; Clandinin, MT; Keelan, M; Lam, T; Tavernini, M; Thomson, AB; Walker, K, 1989
)
0.28
" Dose-response and time-course experiments show that maximal stimulation of PMNs occurred at a PMN: bacteria ratio of 10:1 and exposure time of 10 min."( Direct activation of human polymorphonuclear leukocytes by Pseudomonas aeruginosa.
Mai, GT; McCormack, JG; Seow, WK; Thong, YH, 1989
)
0.28
" Dose-response studies showed, however, that the State 2 pathway was more sensitive to leupeptin or monensin than the State 1 pathway."( Differential effects of leupeptin, monensin and colchicine on ligand degradation mediated by the two asialoglycoprotein receptor pathways in isolated rat hepatocytes.
Clarke, BL; Weigel, PH, 1989
)
0.28
" With lesser concentrations of glucose, the flush exhibits dose-response relationships, and with 3 mg/ml glucose, a second flush can be elicited by restoring basal conditions and stimulating anew with 3 mg/ml glucose."( Rapid transient efflux of phosphate ions from pancreatic islets as an early action of insulin secretagogues.
Bonnar, J; Dawson, RM; Freinkel, N; Younsi, CE, 1974
)
0.25
" Such a gene dosage effect of GAL80 was further pronounced if sucrose, a sugar causing catabolite repression, was added to the growth medium."( Regulation of expression of the galactose gene cluster in Saccharomyces cerevisiae. II. The isolation and dosage effect of the regulatory gene GAL80.
Fukasawa, T; Hashimoto, H; Matsuzaki, Y; Nogi, Y; Shimada, H, 1984
)
0.55
"1-kilobase fragment containing GAL4 by homologous complementation using the multicopy chimeric vector YEp24 and demonstrated that multiple copies of GAL4 in yeast have pronounced dosage effects on the expression of the structural genes."( Isolation of the yeast regulatory gene GAL4 and analysis of its dosage effects on the galactose/melibiose regulon.
Hopper, JE; Johnston, SA, 1982
)
0.49
" Dose-response results with 12-O-tetradecanoylphorbol-13-acetate (TPA) plus X-irradiation parallel those obtained on mouse skin."( Inhibition of radiation-initiated and -promoted transformation of Syrian hamster embryo cells by lymphotoxin.
DeMarinis, AJ; DiPaolo, JA; Doniger, J; Evans, CH, 1984
)
0.27
" A comparison of the standard colony test with the galactose incorporation assay showed similar dose-response patterns with 2 different CSFs."( Stimulation of mouse bone marrow cell membrane glycoconjugate synthesis by colony stimulating factor (CSF): basis for a rapid, simple assay for CSF.
Monner, DA; Mühlradt, PF, 1984
)
0.52
" The chromatographic analysis and the dosage of some urinary carbohydrates, showed that there are not statistically significant differences between the group of myasthenic patients and that of controls."( [Melituric picture in a group of myasthenics].
Antonini, G; De Santis, R; Millefiorini, M; Pazzarelli, L; Piccardo, MG; Rosa, M; Russo, L,
)
0.13
" GSP may be a convenient index for promazine routine dosage adjustment in patients with liver cirrhosis."( Pharmacokinetics of promazine in patients with hepatic cirrhosis--correlation with a novel galactose single point method.
Chen, TC; Curry, SH; Hu, OY; Sheeng, TY; Tang, HS, 1995
)
0.51
" While the dosing and sampling procedures stimulated hyperglycaemia, they had no effect on the concentration of galactose in the peripheral plasma."( The response in the blood of piglets to oral doses of galactose and glucose and intravenous administration of galactose.
Bird, PH; Hartmann, PE, 1994
)
0.75
" Long-term survivors deserve monitoring of liver function for safer methotrexate use, in the light of progressive dosage increments to improve prognosis in neoplastic diseases."( High-dose methotrexate treatment and liver function in patients with osteosarcoma.
Bacci, G; Fabbri, A; Ferrari, S; Figus, E; Longhi, C; Marchesini, G; Marchi, E; Motta, E, 1994
)
0.29
" These results should be taken into consideration to determine the optimal CCl4 dosing schedule in the rat CCl4-induced cirrhosis model."( Mechanism of carbon tetrachloride autoprotection: an in vivo study based on 13C-aminopyrine and 13C-galactose breath tests.
Brazier, JL; Géloën, A; Minaire, Y; Mion, F; Rousseau, M, 1994
)
0.5
" It was found that at the same dosage of 10 mg/kg/day, both AL01576 and AL04114 completely prevented all morphological and biochemical changes in the lenses of naphthalene-fed rats."( Inhibition of naphthalene cataract in rats by aldose reductase inhibitors.
Lou, MF; Xu, GT; York, B; Zigler, S, 1996
)
0.29
" The Clns are essential, rate-limiting activators of Start because cells lacking Cln function (referred to as cln-) arrest at Start and because CLN dosage modulates the timing of Start."( The cyclin-dependent kinase inhibitor p40SIC1 imposes the requirement for Cln G1 cyclin function at Start.
Tyers, M, 1996
)
0.29
"Both fixed and titrated dosing of interferon given for 1 year induced virus clearance in only a minority of treated patients."( Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver.
Bianchi, L; Bühler, H; Dolivo, N; Gonvers, JJ; Lavanchy, D; Malé, PJ; Reichen, J; Renner, EL; Schmid, M; Solioz, M; Zimmermann, A, 1996
)
0.29
" However, because nalmefene will be primarily used in the acute care setting for reversal of opioid-induced effects, it is not likely that these alterations will necessitate a dosage modification."( Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Dixon, R; Frye, RF; Matzke, GR; Rabinovitz, M; Schade, R, 1997
)
0.3
" The expression level of ENA1 was dependent on the gene dosage of HAL1 and overexpression of HAL1 suppressed the salt sensitivity of null mutants in calcineurin and Hal3p, other known regulators of ENA1 expression."( Mechanisms of salt tolerance conferred by overexpression of the HAL1 gene in Saccharomyces cerevisiae.
Ferrando, A; Rios, G; Serrano, R, 1997
)
0.3
" Dose-response relationships of several sugars followed a simple Michaelis-Menten type of kinetics."( The sugar specificity of Na+/glucose cotransporter from rat jejunum.
Aoshima, H; Izu, H; Tanizaki, J; Yamada, M; Yokoyama, T, 1997
)
0.3
" Increase in NAM9 gene dosage is accompanied by the increase in both mRNA and protein."( Expression of the yeast NAM9 gene coding for mitochondrial ribosomal protein.
Boguta, M; Chacińska, A; Murawski, M; Szcześniak, B, 1997
)
0.3
" These findings thus indicate that Gal-lip-IL-2 may enhance the therapeutic efficacy of IL-2 against hepatic metastases and thereby facilitate a more practical daily dosing regimen."( Hepatic immunopotentiation by galactose-entrapped liposomal IL-2 compound in the treatment of liver metastases.
Nakamura, K; Okuno, K; Tanaka, A; Yachi, K; Yasutomi, M, 1998
)
0.59
"Using ODM II by positioning the probe toward the azygos vein, a dosage of 1 ml microparticularly d-galactose was detected in every patient."( Validating of a transoesophageal ultrasonic-Doppler-probe to the detection of air in the venous blood.
Hennig, C; Henze, D; Lindner, J; Menzel, M; Radke, J; Roth, S; Soukup, J, 1998
)
0.52
" Our results suggest that modulation of the dosage or expression of unknown nuclear-coded factor(s) can compensate for a pathogenic mitochondrial tRNA gene mutation, suggesting new strategies for therapeutic intervention."( Suppression of a mitochondrial tRNA gene mutation phenotype associated with changes in the nuclear background.
Hao, H; Moraes, CT; Morrison, LE, 1999
)
0.3
" Choline phosphate decreased rapidly during dosing in all but the 5% group, but no changes in those levels were observed after 2 weeks of galactose dosing."( Organophosphate metabolic changes in the rat lens during the development of galactose-induced cataract.
Igarashi, H; Sakagami, K; Tanaka, K; Yoshida, A, 1999
)
0.74
" We also show that the activation of PUT2 by Gal4p depends on the presence of the inducer galactose and the Put3p binding site and that activation increases with increased dosage of Gal4p."( Cross-pathway regulation in Saccharomyces cerevisiae: activation of the proline utilization pathway by Ga14p in vivo.
Brandriss, MC; D'Alessio, M, 2000
)
0.53
" The 2-, 6-, and 20-mg/kg dosages of POC maintained plasma drug levels above the MICs for the entire 24-h dosing interval."( Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Avila, N; Bacher, J; Candelario, M; Field-Ridley, A; Groll, AH; Petraitiene, R; Petraitis, V; Piscitelli, S; Sein, T; Walsh, TJ, 2001
)
0.31
" However, increased YHR076w gene dosage confers a growth advantage to both wild-type and YHR076w knockout strains on 2% ethanol or 2% galactose medium in a low O2 growth environment."( Molecular analysis of the Saccharomyces cerevisiae YHR076w gene.
Gonzalez, S; Güldener, U; Hegemann, JH; Klein, S; Ramos, CW; Rodríguez-Medina, JR, 2000
)
0.51
" The CAS1, CAS3, and CAS6 dose regimens demonstrated dose-proportional exposure and maintained drug levels in plasma above the MIC for the entire 24-h dosing interval at doses that were > or =3 mg/kg/day."( Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Avila, NA; Bacher, J; Francesconi, A; Groll, AH; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Walsh, TJ, 2002
)
0.31
"These data indicate that supplementation of a term infant's formula with a mixture of galacto- and fructooligosaccharides has a dose-dependent stimulating effect on the growth of Bifidobacteria and Lactobacilli in the intestine and results in softer stool with increasing dosage of supplementation."( Dosage-related bifidogenic effects of galacto- and fructooligosaccharides in formula-fed term infants.
Boehm, G; Fanaro, S; Jelinek, J; Minoli, I; Moro, G; Mosca, M; Stahl, B, 2002
)
0.31
" No evidence was found for a dose-response relation between the odds ratios for ovarian cancer and GALT activity or the ratio of lactose intake to GALT activity."( Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer.
Cramer, DW; Goodman, MT; McDuffie, K; Ng, WG; Reichardt, JK; Terada, K; Tung, KH; Wilkens, LR; Wu, AH, 2002
)
0.67
" Furthermore, when tested in a hapten inhibition test, the isolated oligosaccharide alditols were able to block, on a dose-response basis, recognition between human sera and the intact peptidogalactomannan."( Beta-galactofuranose-containing O-linked oligosaccharides present in the cell wall peptidogalactomannan of Aspergillus fumigatus contain immunodominant epitopes.
Barreto-Bergter, E; Bittencourt, VC; de Souza, LM; Haido, RM; Leitao, EA; Letzel, M; Peter-Katalinic, J; Valente, AP, 2003
)
0.32
" The pharmacokinetics of metformin from the mucoadhesive dosage forms indicated that for metformin alone, the area under the curve (AUC) values were 125."( Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models.
Adikwu, MU; Takada, K; Yoshikawa, Y, 2004
)
0.32
" Ravuconazole showed linear plasma pharmacokinetics and a large volume of distribution while maintaining concentrations in plasma above the MIC throughout the dosing interval."( Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Armstrong, D; Avila, NA; Bacher, J; Groll, AH; Hemmings, M; Lyman, CA; Mickiene, D; Peter, J; Petraitiene, R; Petraitis, V; Roussillon, K; Walsh, TJ, 2004
)
0.32
" Dose-response analyses demonstrated that these glycans are potent inhibitors (IC(50) approximately 180 nM), which at saturation, reduced Alexa(568)-ZP3 binding by approximately 70%."( Lewis X-containing glycans are specific and potent competitive inhibitors of the binding of ZP3 to complementary sites on capacitated, acrosome-intact mouse sperm.
Hanna, WF; Kerr, CL; Shaper, JH; Wright, WW, 2004
)
0.32
" Drug release decreased with the increase of amount of drug and it is dependent of dosage form."( Evaluation of xanthan and highly substituted galactomannan from M. scabrella as a sustained release matrix.
Andreazza, IF; Bresolin, TM; Ganter, JL; Ughini, F, 2004
)
0.32
" However, the dosage of D-gal used to establish this model in mice has been reported in a wide range."( Behavioural study of the D-galactose induced aging model in C57BL/6J mice.
Ai, H; Chu, J; Li, L; Li, W; Song, Q; Wei, H, 2005
)
0.63
" However, sufficient antibody reduction was independent of dosage and form of application of GAS914."( Administration of GAS914 in an orthotopic pig-to-baboon heart transplantation model.
Baschnegger, H; Bauer, A; Bittmann, I; Brandl, U; Brenner, P; Erhardt, M; Hammer, C; Michel, S; Reichart, B; Rössle, M; Schmoeckel, M, 2005
)
0.33
"54 mg kg-1 D-1 dosage as a positive control drug, DZXYS in 12."( [Protective effect of Danzhi-xiaoyao San on rat brain energy or material metabolism (correction of matebolism) dealt with D-galactose].
Cai, DY; Chen, JX; Huang, QF; Sun, LP; Wang, X; Zhang, JJ; Zhang, W, 2005
)
0.54
"This study was aimed at optimizing the preparation of 5-Fluorouracil and peanut agglutinin conjugates so as to obtain a conjugate with high activity and high drug ratio, and to choose suitable dosage form in the light of its properties."( [Optimization of the preparation and the properties of conjugate of 5-Fluorouracil and peanut agglutinin].
Qin, C; Zhang, ZR, 2005
)
0.33
"05, dosage of 200 mg/kgd body weight) in peripheral lymphocytes compared to the irradiated control."( Water-soluble polysaccharides from Angelica sinensis (Oliv.) Diels: Preparation, characterization and bioactivity.
Gu, X; Li, D; Sun, Y; Tang, J, 2005
)
0.33
" This growth defect was used as the basis for a genetic screen for dosage suppressors of the RAS2(val19) mutant."( Increased phosphoglucomutase activity suppresses the galactose growth defect associated with elevated levels of Ras signaling in S. cerevisiae.
Deminoff, SJ; Herman, PK; Howard, SC, 2006
)
0.58
" We investigate the changes in inner ear enzymatic activity, the occurring of mtDNA 4834 bp deletion in inner ear and other tissues and the relating hearing thresholds after the administration of high dosage (150 mg/kg per day) and low dosage (50 mg/kg per day) of D-gal to rats."( The relation between D-galactose injection and mitochondrial DNA 4834 bp deletion mutation.
Han, YC; Hu, YJ; Kong, WJ; Liu, J; Wang, Q; Wang, Y, 2006
)
0.64
"Resveratrol of every dosage could improve the performance records of behavior tests in AD mice,could inhibit the SOD vitality and the MDA level both in the serum and in the brain, and could suppress the acetylcholinesterase vitality and the bax expression."( [Effect of resveratrol on the cognitive ability of Alzheimeros mice].
Huang, YM; Luo, L, 2006
)
0.33
" We concluded that the combination of AFG with VRC in treatment of experimental IPA in persistently neutropenic rabbits was independent to synergistic at a dosage of 5 mg/kg/day but independent to antagonistic at 10 mg/kg/day, as assessed by Bliss independence analysis, suggesting that higher dosages of an echinocandin may be deleterious to the combination."( Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis.
Avila, NA; Bacher, J; Cotton, MP; Francesconi, A; Hope, WW; Hughes, JE; Kasai, M; Meletiadis, J; Mickiene, D; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Stergiopoulou, T; Walsh, TJ, 2009
)
0.35
" Administration of this dosage also significantly reduced the degree of lens peroxidation, increased the level of reduced glutathione (GSH) and the lens catalase and superoxide dismutase activity."( Chemopreventive and remediation effect of Hydrocotyl bonariensis Comm. Ex Lam (Apiaceae) leave extract in galactose-induced cataract.
Adebawo, OO; Adeoye, AO; Ajani, EO; Akinleye, WA; Salako, AA; Salau, BA; Sharlie, PD, 2009
)
0.57
"Coping with variations in network dosage is crucial for maintaining optimal function in gene networks."( A general mechanism for network-dosage compensation in gene circuits.
Acar, M; Arnold, FH; Elowitz, MB; Pando, BF; van Oudenaarden, A, 2010
)
0.36
" Acute toxicity assay revealed that the mice grew well in 2 weeks with GC-PEI dosage from 50 to 300 μg."( Hepatocyte-targeted gene transfection of galactosylated chitosan-graft low molecular polyethyleneimine/DNA complexes.
Feng, D; Li, M; Tan, P; Wang, Y, 2011
)
0.37
" Thus, the developed system provides a better control of the postprandial glycaemic levels and it also obviates the need of conventional multiple dosing of acarbose."( A novel synergistic galactomannan-based unit dosage form for sustained release of acarbose.
Kumar, RV; Sinha, VR, 2012
)
0.38
" This allows the dose-response behaviour of gene expression driven by any yeast promoter to be reported and can be used to quantify important parameters, such as the threshold, sensitivity, response time, maximal activity and synthesis rate for a given stimulus."( The use of a real-time luciferase assay to quantify gene expression dynamics in the living yeast cell.
Pascual-Ahuir, A; Proft, M; Rienzo, A, 2012
)
0.38
" Divided rats into 5 groups randomly: the normal control (group A), the aging model (group B), the low dosage (1 000 U/ (kg x d)) of recombinant human erythropoietin (rhEPO) intervene (group C), the middle dosage (3 000 U/(kg x d)) of rhEPO intervene (group D) and the high dosage (5 000 U/(kg x d)) of rhEPO intervene (group E), 10 rats in each group."( [The anti-aging effect of EPO and the preliminary probe into its mechanisms].
Lü, D; Wang, HQ; Wang, HY; Wu, HQ; Zhai, YF; Zhang, GL, 2012
)
0.38
"The middle dosage of EPO has the anti-aging effect, and its mechanisms may be related to enhancing the antioxidant enzymes activity and increasing the antioxidant capacity."( [The anti-aging effect of EPO and the preliminary probe into its mechanisms].
Lü, D; Wang, HQ; Wang, HY; Wu, HQ; Zhai, YF; Zhang, GL, 2012
)
0.38
" As one demonstrative application, we show the suitability of the technique for generating a dose-response curve for an enzyme inhibition assay."( Generation of chemical concentration gradients in mobile droplet arrays via fragmentation of long immiscible diluting plugs.
Sun, M; Vanapalli, SA, 2013
)
0.39
" The objectives of the present study were to investigate the dose-response relationship of GOS supplementation on Ca absorption during growth and to assess changes in colonic microbiota to better understand the mechanism by which GOS is acting."( Galacto-oligosaccharides increase calcium absorption and gut bifidobacteria in young girls: a double-blind cross-over trial.
Martin, BR; McCabe, GP; McCabe, LD; Nakatsu, CH; Schoterman, MH; van den Heuvel, EG; Wastney, ME; Weaver, CM; Whisner, CM, 2013
)
0.39
" The dosage of valerenic acid (340 μg/kg), which is the active ingredient of valerian root extract, was determined by the content of valerenic acid in valerian root extract (3."( Valeriana officinalis extract and its main component, valerenic acid, ameliorate D-galactose-induced reductions in memory, cell proliferation, and neuroblast differentiation by reducing corticosterone levels and lipid peroxidation.
Choi, JH; Hwang, IK; Jung, HY; Kang, SY; Kim, DW; Kim, JW; Kim, W; Kim, WJ; Nam, SM; Park, J; Yoo, DY; Yoon, YS, 2013
)
0.61
"5) combined with an accumulative dosage of corticosteroids >216 mg before the ICU admission and a low Ccr may predicate a poor outcome of critically ill COPD patients."( Prognostic value of serum galactomannan index in critically ill patients with chronic obstructive pulmonary disease at risk of invasive pulmonary aspergillosis.
Chang, S; Ding, L; He, H; Li, F; Li, Q; Sun, B; Zhan, Q, 2014
)
0.4
"5% Gal solution from 1 to 7 days and 10%Gal solution from 8 to 21 days except for normal diet ) ; 30 rats as the treatment group and fed with the same Gal solution as the model group, besides they were divided into high dosage group, medium dosage group and low dosage group equally and gave 300 mg×kg(-1)×d(-1), 150 mg×kg(-1)×d(-1), 75 mg×kg(-1)×d(-1) dose of calcium dobesilate respectively from the first day to the end of experiment."( [Evaluation of calcium dobesilate for its anti-cataract potential in experimental rat models].
Hao, LL; Jiang, Y; Wang, RN; Xu, D; Zheng, GY, 2013
)
0.39
" There were no statistic significant differences among high dosage group, medium dosage group and low dosage group ."( [Evaluation of calcium dobesilate for its anti-cataract potential in experimental rat models].
Hao, LL; Jiang, Y; Wang, RN; Xu, D; Zheng, GY, 2013
)
0.39
"An oral dosage form containing floating bioadhesive gastroretentive microspheres forms a stomach-specific drug delivery system for the treatment of Helicobacter pylori."( Floating-bioadhesive gastroretentive Caesalpinia pulcherrima-based beads of amoxicillin trihydrate for Helicobacter pylori eradication.
Gide, PS; Thombre, NA, 2016
)
0.43
" In the NaHS group, D-gal was administered as above but with NaHS intraperitoneally injected at a dosage of 1, 10, 100 μmol·kg⁻¹·d⁻¹ respectively."( [Exogenous hydrogen sulfide reduces vascular aging in D-galactose-induced subacute aging rats].
Cui, J; Liu, H; Liu, L; Qiao, WL; Shi, Y; Yan, CD; Yang, WX, 2014
)
0.65
" The male mice were randomly divided into five groups, namely, the normal group, the model group and dosage groups (15, 30 and 60 mg kg(-1) of BACN)."( Ameliorative effect of black rice anthocyanin on senescent mice induced by D-galactose.
Hao, L; Lu, X; Wu, T; Zhou, Y, 2014
)
0.63
" Clear synergistic enhancement of locust bean gum hydrolysis with respect to reducing sugar release was observed when both mannanases at 75% enzyme dosage were supplemented with 25% enzyme protein dosage of Aga27A."( β-mannanase (Man26A) and α-galactosidase (Aga27A) synergism - a key factor for the hydrolysis of galactomannan substrates.
Malgas, S; Pletschke, BI; van Dyk, SJ, 2015
)
0.42
" KNPS was found non-toxic toward human lymphocyte up to the dosage of 100 μg/ml."( Structural elucidation and biological studies of a novel exopolysaccaride from Klebsiella pneumoniae PB12.
Chakraborty, R; Chattopadhyay, S; Islam, SS; Maity, P; Mandal, AK; Roy, S; Sen, IK, 2015
)
0.42
" A dosage of 20 mg/l BF-OU5 initiated more than 92."( Characterization and flocculability of a novel proteoglycan produced by Talaromyces trachyspermus OU5.
Fang, D; Shi, C, 2016
)
0.43
" Chromatin remodeling appears to be the basis for the dynamic GAL1 expression, because mutants with impaired histone dynamics show severely truncated dose-response profiles."( Different Mechanisms Confer Gradual Control and Memory at Nutrient- and Stress-Regulated Genes in Yeast.
Aydin, S; Buchler, NE; Pascual-Ahuir, A; Poveda-Huertes, D; Proft, M; Rienzo, A, 2015
)
0.42
" In addition, FO attenuated the d-galactose-induced protein expression of Aβ and beta-site amyloid precursor cleaving enzyme of the whole brain in a dose-response manner."( Fructo-oligosaccharide improved brain β-amyloid, β-secretase, cognitive function, and plasma antioxidant levels in D-galactose-treated Balb/cJ mice.
Chen, HL; Wang, CH; Wu, WT; Yen, CH, 2017
)
0.94
" The ratios of the animal lethal dosage values to the cytotoxicity in HT29 (LD50/IC50) showed that Gal-Pt was associated with an increased therapeutic index by over 30-fold compared to cisplatin and oxaliplatin."( Galactose conjugated platinum(II) complex targeting the Warburg effect for treatment of non-small cell lung cancer and colon cancer.
Fu, Z; Gao, Q; Gao, X; Li, H; Liu, P; Liu, R; Wu, M; Yang, J; Zhang, M; Zhang-Negrerie, D, 2016
)
1.88
" Moreover, the expression of the pro-survival p-Akt (protein kinase B (Akt)), Bcl-2 (B-cell lymphoma 2), anti-apoptotic protein (Bcl-xL) protein decreased significantly in the d-Galactose-induced aging group, with increased performance in the AOF treatment group with levels of p-IGFIR and p-PI3K (Phosphatidylinositol-3' kinase (PI3K)) to increase by dosage and compensatory performance."( Anti-Apoptotic and Pro-Survival Effect of Alpinate Oxyphyllae Fructus (AOF) in a d-Galactose-Induced Aging Heart.
Chang, HH; Chang, HN; Chang, YM; Chen, RJ; Huang, CY; Kuo, WW; Lin, HJ; Padma Viswanadha, V; Tsai, CC; Yeh, YL, 2016
)
0.85
" Dose-response data was normalised to 100× Cmax giving a specificity, sensitivity and accuracy of 100%, 81% and 92% respectively for this combined approach."( A combined in vitro approach to improve the prediction of mitochondrial toxicants.
Bauch, C; Bevan, S; Dilworth, C; Eakins, J; Park, B; Walker, P; Woodhouse, H, 2016
)
0.43
" Fermentation of 65 % B-GOS was compared with 52 % B-GOS in pH- and volume-controlled dose-response anaerobic batch culture experiments."( Fermentation properties and potential prebiotic activity of Bimuno® galacto-oligosaccharide (65 % galacto-oligosaccharide content) on in vitro gut microbiota parameters.
Costabile, A; Gibson, GR; Grimaldi, R; Swann, JR; Vulevic, J, 2016
)
0.43
" In vitro experiment, the results showed that RAPS at dosage of 15."( Structure characterization of three polysaccharides and a comparative study of their immunomodulatory activities on chicken macrophage.
Fan, W; Hao, P; Liu, J; Zhang, S; Zhao, X; Zheng, P, 2016
)
0.43
" The area under the curves (AUC) of immunosuppressants was calculated by the plot of plasma trough level or dosage of each immunosuppressant versus time and was interpreted as the extent of drug exposure."( Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
Barratt, J; Kim, MJ; Koller, MT; Molyneux, K; Schaub, S; Stampf, S, 2016
)
0.68
" In this observation, the galactomannan dosage was positive until the introduction of treatment and surgical debridement."( Update on Actinomucor elegans, a mucormycete infrequently detected in human specimens: how combined microbiological tools contribute efficiently to a more accurate medical care.
Cuenin, M; D'Aveni, M; Debourgogne, A; Dorin, J; Gallet, P; Guillaso, M; Lecoanet, G; Machouart, M; Rivier, A, 2017
)
0.46
" Two dosing regimens were designed, one for the evaluation of preventive effects in which the rats were simultaneously administrated d-gal and UPNO-1/fishoil for 12 weeks, the other for the evaluation of therapeutic effects in which the rats were given d-gal for 8 weeks before treated with UPNO-1/selegiline for 8 weeks."( Mechanisms of the active components from Korean pine nut preventing and treating d-galactose-induced aging rats.
Lin, W; Ling, X; Liu, Y; Ren, J; Wu, R; Zhang, J; Zhang, S; Zhu, K, 2018
)
0.71
" To help choose the best dose of d-gal for the induction of the aging model, we performed a dose-response curve (100, 200 or 300 mg/kg)."( Sodium butyrate improves memory and modulates the activity of histone deacetylases in aged rats after the administration of d-galactose.
Bellettini-Santos, T; Budni, J; Campos, ACBF; da Silva, S; Damiani, AP; de Andrade, VM; de Carvalho, CA; Garcez, ML; Longaretti, LM; Mina, F; Schiavo, GL; Valvassori, SS; Varela, RB, 2018
)
0.69
" The data indicated that the UV irradiation with increasing dosage of photo-initiator could gradually consume the free hydroxyl groups in GMP to form the crosslinked networks, reducing the hydrophilic property and water vapor permeability of the modified film."( Preparation and physical/chemical modification of galactomannan film for food packaging.
Chai, Y; Jiang, J; Wang, K; Wang, T; Yang, HY; Zhao, N, 2019
)
0.51
" Mice were administered a subcutaneous abdominal injection of D-galactose to induce the ageing model and fed with different selenoprotein dosage diet."( Dissecting the Potential of Selenoproteins Extracted from Selenium-Enriched Rice on Physiological, Biochemical and Anti-Ageing Effects In Vivo.
Farooq, MU; Hussain, S; Jia, X; Liang, Y; Su, Y; Tang, Z; Ye, X; Zeng, R; Zhang, G; Zheng, T; Zhu, J, 2020
)
0.8
" Chest CT-scan and GM dosage were analyzed at the time of IPA suspicion."( High prevalence of peribronchial focal lesions of airway invasive aspergillosis in hematological cancer patients with prolonged neutropenia.
Beigelman-Aubry, C; Bochud, PY; Brunel, AS; Casutt, A; Couchepin, J; Keller, N; Lamoth, F; Lovis, A, 2020
)
0.56
"5% (5/9) subjects in aged mice groups died in the high dosage group."( Acute and subchronic toxicity studies of rhein in immature and d-galactose-induced aged mice and its potential hepatotoxicity mechanisms.
Chen, SY; Gao, Y; Huang, WY; Li, YQ; Meng, XL; Su, SY; Wang, P; Yang, D, 2022
)
0.96
" GalM in Sesbania seed was hydrolyzed simultaneously by a mixture of crude enzyme with β-mannanase and α-galactosidase at a dosage of 20 U/g GalM and 15 U/g GalM, respectively; the yields of incomplete degradation products of GalM (IDP-GalM) and GalMOS were 78."( The Increase of Incomplete Degradation Products of Galactomannan Production by Synergetic Hydrolysis of β-Mannanase and α-Galactosidase.
Lai, C; Li, X; Shi, G; Tao, Y; Yang, L; Yong, Q; Zhou, M, 2021
)
0.62
" D-gal was given at a dosage of 300mg/ml/kg$ and animals received their respective treatment for 6 weeks [intraperitoneally (I."( Effect of lithium chloride on d-galactose induced organs injury: Possible antioxidative role.
Ayaz, MM; Bilal, K; Khaliq, S; Samad, N; Yasmin, F; Zaman, A, 2020
)
0.84
"Honey-processed Astragalus is a dosage form of Radix Astragali processed with honey, which exhibits better efficacy of tonifying Qi than the raw product."( Structural differences of polysaccharides from Astragalus before and after honey processing and their effects on colitis mice.
Bai, L; Bo, R; Chen, H; Huang, L; Li, C; Rui, W; Wu, J; Ye, M, 2021
)
0.62
" Thus, there is a need for biomarkers to guide d-galactose dosage in patients in order to maintain effective and safe drug levels."( A new D-galactose treatment monitoring index for PGM1-CDG.
Gavrilov, D; Liedtke, K; Matern, D; Morava, E; Oglesbee, D; Perales-Clemente, E; Radenkovic, S; Raymond, K; Rinaldo, P; Studinski, A; Tortorelli, S, 2021
)
1.31
" In a double-blind randomized placebo-controlled clinical trial, we aimed to determine a dose-response effect of galacto-oligosaccharides (GOS) on stool characteristics and fecal microbiota in 132 adults with self-reported constipation according to Rome IV criteria (including less than three bowel movements per week)."( Prebiotic Galacto-Oligosaccharides Impact Stool Frequency and Fecal Microbiota in Self-Reported Constipated Adults: A Randomized Clinical Trial.
Boekhorst, J; Bos, R; Hageman, JHJ; Hartog, A; Nauta, A; Schoemaker, MH; Scholtens, PAMJ; Ten Haaf, D, 2022
)
0.72
" Honey-processed Astragalus is a dosage form of Astragali Radix processed with honey, which exhibited better efficacy of tonifying Qi than the raw product."( Structural changes of polysaccharides from Astragulus after honey processing and their bioactivities on human gut microbiota.
Chen, H; Li, M; Rui, W; Tian, Y; Wu, J; Xu, X; Zheng, Y, 2023
)
0.91
" The ameliorative effect of FDH-GABA on premature aging showed a clear dose-response relationship, and at the same time, the changes of intestinal microorganisms showed a certain correlation with the relevant indexes of nervous system."( Beneficial effect of GABA-rich fermented milk whey on nervous system and intestinal microenvironment of aging mice induced by D-galactose.
He, W; Jiang, Y; Min, J; Song, H; Yang, Z; Zhao, S, 2024
)
1.65
" In dose-response studies, the inhibition by somatostatin of the effect of glucose on [3H]cyclic AMP and insulin release could be overcome by a high concentration of the hexose (44."( Studies on the mechanisms of somatostatin action on insulin release. IV. effect of somatostatin on cyclic AMP levels and phosphodiesterase activity in isolated rat pancreatic islets.
Claro, A; Efendić, S; Grill, V; Luft, R, 1977
)
0.26
" The selection of these chelating agents for synthesis was suggested by an analysis of the log dose-response curves for the mobilization of renal cadmium by previously studied dithiocarbamates."( Selective removal of cadmium from aged hepatic and renal deposits: N-substituted talooctamine dithiocarbamates as cadmium mobilizing agents.
Atkins, LM; Gale, GR; Jones, MM; Jones, SG; Singh, PK; Smith, AB, 1990
)
0.28
" The model, applied to data obtained after percutaneous dosing of ointments under occlusion, successfully described the plasma profile observed in the presence and absence of laurocapram (Azone) and sorbitan monooleate."( A pharmacokinetic model for the percutaneous absorption of indomethacin and the prediction of drug disposition kinetics.
Atago, H; Ito, Y; Iwaki, M; Ogiso, T, 1989
)
0.28
" Furthermore, differing quin-2 AM dose-response profiles suggest the presence of dual Ca2+-dependent pathways in the adipocyte."( Chelation of intracellular calcium blocks insulin action in the adipocyte.
Delfert, DM; McDonald, JM; Pershadsingh, HA; Shade, DL, 1987
)
0.27
" Pretreatment with 20% ethanol markedly inhibited the gross mucosal damage caused by 70% ethanol dosing but the inhibition in the reduction of mucus glycoprotein content was restricted to about 80% of the untreated controls."( Mucus glycoprotein and mucosal protection.
Hotta, K; Ishihara, K; Kuwata, H; Ohara, S; Ohkawa, H; Okabe, H, 1988
)
0.27
" The potentiation of insulin action follows a dose-response relationship with kallikrein and bradykinin concentrations consistent with a physiological role for the latter in the modulation of insulin action."( Potentiation of insulin stimulation of hexose transport by kallikrein and bradykinin in isolated rat adipocytes.
Goldman, J; Pfister, D; Vukmirovich, R, 1987
)
0.27
" Further control experiments demonstrated that FITC pre-treatment of cells had no effect on the intracellular ATP concentration or the dose-response curve of insulin stimulation of hexose transport."( Insulin stimulation of glucose transport in isolated rat adipocytes. Functional evidence for insulin activation of intrinsic transporter activity within the plasma membrane.
Hyslop, PA; Kuhn, CE; Sauerheber, RD, 1985
)
0.27
" It is apparent from the dose-response data that up-regulation is not inhibited by irradiation in a simple manner and is not inhibited at the same radiation dose as cell replication."( Role of cell replication in regulation of Na-coupled hexose transport in LLC-PK1 epithelial cells.
Hagan, M; Handler, JS; Moran, A, 1986
)
0.27
" Inhibition of phagocytosis and changes in cell shape by cytochalasin B exhibited nearly identical dose-response curves requiring 2-5 x 10(-6) M and 1-2 x 10(-5) M cytochalasin B to inhibit these functions by 50% and 100%, respectively."( Inhibition of phagocytosis and plasma membrane mobility of the cultivated macrophage by cytochalasin B. Role of subplasmalemmal microfilaments.
Axline, SG; Reaven, EP, 1974
)
0.25
" A plateau secretion of acid evoked by infusing histamine in a near maximal dosage was inhibited by atropine to the same extent as the gastrin-induced secretion in the Pavlov pouch."( Inhibition of gastric secretion by atropine in conscious rats.
Johansson, I; Lundell, L; Svensson, SE, 1971
)
0.25
" Hence, a dose-response effect at 60 and 120 min was obtained by prostasomes on sperm forward motility provided 5 mmol/l of fructose was present--otherwise not."( Prolongation and improvement of prostasome promotive effect on sperm forward motility.
Fabiani, R; Johansson, L; Lundkvist, O; Ronquist, G, 1995
)
0.29
" The intensity of contraction after rectal administration of sodium caprate or sodium cholate was dependent on the concentration in the dosing solution."( A novel method for the preclinical assessment of rectal irritation.
Kinouchi, Y; Takeichi, Y; Yata, N, 1996
)
0.29
" An in vivo dose-response curve was calculated from audio Doppler signals obtained with a 10-MHz cuff transducer placed around the distal aorta."( Quantitative acoustic characterization of a new surfactant-based ultrasound contrast agent.
Forsberg, F; Makin, IR; Wang, W; Wheatley, MA; Wu, Y, 1997
)
0.3
" Eleven of the 19 dosed animals (4 adapted conventional, 3 unadapted conventional and 2 unadapted germ-free, all dosed orally, plus 2 unadapted conventional dosed intravenously) were placed in metabolism chambers and samples of CO2, urine, and feces taken at regular intervals."( Disposition of D-[U-14C]tagatose in the rat.
Levin, GV; Saunders, JP; Zehner, LR, 1999
)
0.3
" We modified the insulin dosage form with citric acid to improve the insulin stability at room temperature without loss of hypoglycemic activity."( Improvement of stability and absorbability of dry insulin powder for inhalation by powder-combination technique.
Danjo, K; Iida, K; Okamoto, H; Todo, H, 2004
)
0.32
" Therefore, an oral colonic targeted heparin dosage form allowing the release of LMWH directly in the inflamed tissue would be of major interest."( Low molecular weight heparin loaded pH-sensitive microparticles.
Ghazouani, FE; Lamprecht, A; Maincent, P; Meissner, Y; Ubrich, N, 2007
)
0.34
" There was a decrease in the skin permeability coefficient of the drug by nanoencapsulation, independently of the dosage form."( Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine.
Beck, RC; de Bona da Silva, C; Guterres, SS; Kostka, KH; Lehr, CM; Melero, A; Ourique, AF; Pohlmann, AR; Schaefer, UF, 2011
)
0.37
" Presently, griseofulvin is available only in conventional oral dosage forms that suffer from the issues of poor and highly variable bioavailability, numerous systemic side effects and long duration of treatment."( Preparation and evaluation of antifungal efficacy of griseofulvin loaded deformable membrane vesicles in optimized guinea pig model of Microsporum canis--dermatophytosis.
Aggarwal, N; Goindi, S, 2012
)
0.38
" The potential solid dispersions would enable an oral solid dosage form as a monotherapy or combination product of MK-0364."( Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364.
McKelvey, C; Moser, J; Rege, B; Sotthivirat, S; Xu, W; Zhang, D, 2013
)
0.39
" RNAi-mediated suppression of GhVIN1, a major VIN gene that is highly expressed in wild-type fiber initials, resulted in significant reduction of VIN activity and consequently a fiberless seed phenotype in a dosage dependent manner."( Silencing the vacuolar invertase gene GhVIN1 blocks cotton fiber initiation from the ovule epidermis, probably by suppressing a cohort of regulatory genes via sugar signaling.
Chen, XY; Cook, A; Patrick, JW; Ruan, YL; Wang, L, 2014
)
0.4
" The prepared provesicular buccoadhesive tablet of granisetron (F19) might help bypass hepatic first-pass metabolism and improve bioavailability of granisetron with the possibility of reducing reported daily dose (2mg) and reducing dosing frequency."( Provesicular granisetron hydrochloride buccal formulations: in vitro evaluation and preliminary investigation of in vivo performance.
Ahmed, S; El-Latif Badawi, AA; El-Nabarawi, MA; El-Setouhy, DA, 2014
)
0.4
" Quality by design (QbD) concept was implemented for the development of MDDC with potential to be incorporated into semisolid dosage form (gel)."( Implementation of quality by design principles in the development of microsponges as drug delivery carriers: Identification and optimization of critical factors using multivariate statistical analyses and design of experiments studies.
Dimitrovska, A; Glavas Dodov, M; Mladenovska, K; Sibinovska, N; Simonoska Crcarevska, M; Slavevska Raicki, R, 2015
)
0.42
"Solid self-emulsifying drug delivery system was an effective oral solid dosage form to improve the oral bioavailability of ivermectin."( Formulation Studies of Solid Self-Emulsifying Drug Delivery System of Ivermectin.
Ashara, KC; Lakkad, HA; Patel, VP, 2018
)
0.48
"The aim of this study was to develop a new dosage form as an alternative to the classical tablet forms of atorvastatin calcium (AtrCa)."( Formulation and In Vitro Evaluation of Self Microemulsifying Drug Delivery System Containing Atorvastatin Calcium.
Diril, M; Karasulu, HY; Türkyılmaz, GY, 2019
)
0.51
" The sequential administration of PEG-Span 80 niosome at 24 or 48 h after dosing of DOX-PEG liposome provided a higher anti-tumor effect than the single dose of DOX-PEG liposome in the C26-bearing mice."( Sequential administration of PEG-Span 80 niosome enhances anti-tumor effect of doxorubicin-containing PEG liposome.
Hashimoto, K; Higaki, K; Maruyama, M; Minamisakamoto, T; Nishiguchi, S; Ogawara, KI, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (14 Items)

ItemProcessFrequency
Bars covered with chocolatecore-ingredient3
Chocolate candiescore-ingredient3
Barscore-ingredient3
Confectioneriescore-ingredient3
Cocoa and its productscore-ingredient3
Sweet snackscore-ingredient3
Snackscore-ingredient3
Formaggio grattugiatotrace-ingredient1
Grana Padanotrace-ingredient1
Formaggi italianitrace-ingredient1
Formaggitrace-ingredient1
Prodotti lattiero-caseari fermentatitrace-ingredient1
Cibi fermentatitrace-ingredient1
Latticinitrace-ingredient1

Roles (3)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
D-galactose
galactopyranoseThe pyranose form of galactose.
D-galactopyranoseA galactopyranose having D-configuration.
D-galactopyranoseA galactopyranose having D-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (59)

PathwayProteinsCompounds
Galactose metabolism ( Galactose metabolism )913
plant arabinogalactan type II degradation04
xyloglucan degradation II (exoglucanase)112
rhamnogalacturonan type I degradation I02
indole-3-acetate activation II011
agarose degradation44
porphyran degradation510
D-galactose degradation IV59
D-galactose degradation II28
melibiose degradation114
lactose degradation II311
Central carbon metabolism019
Inner Membrane Transport7862
Galactose Degradation/Leloir Pathway1318
Leloir Pathway612
D-Galactose Degradation (Leloir pathway)49
D-galactose degradation I (Leloir pathway)311
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
D-galactose degradation V (Leloir pathway)813
D-galactose degradation I (Leloir pathway)1046
xyloglucan degradation I (endoglucanase)04
lactose degradation III123
galactose degradation I (Leloir pathway)526
galactose degradation I011
galactose degradation IV013
Metabolism14961108
Carbohydrate metabolism173120
Glycosaminoglycan metabolism3637
Keratan sulfate/keratin metabolism918
Keratan sulfate degradation19
Heparan sulfate/heparin (HS-GAG) metabolism1820
HS-GAG degradation710
Metabolism of lipids500463
Sphingolipid metabolism5550
Glycosphingolipid metabolism3031
Galactose Metabolism1234
Nucleotide Sugars Metabolism817
Sphingolipid Metabolism2335
Lactose Degradation129
Galactosemia1234
Gaucher Disease2335
Globoid Cell Leukodystrophy2335
Metachromatic Leukodystrophy (MLD)2335
Lactose Intolerance129
Galactosemia II (GALK)817
Galactosemia III817
Fabry Disease2335
Krabbe Disease2335
Amino Sugar and Nucleotide Sugar Metabolism2229
melibiose degradation04
stachyose degradation514
indole-3-acetate activation II09
D-galactose detoxification617
UDP-galactose biosynthesis (salvage pathway from galactose using UDP-glucose)018
Biomarkers for urea cycle disorders1222
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Glycosphingolipid catabolism1716
D-galactose detoxification523
D-galactose degradation III419
UDP-galactose biosynthesis013
galactose degradation III017
UDP-galactose biosynthesis (salvage pathway from galactose using UDP-glucose)510
Leloir pathway48
Colanic acid building blocks biosynthesis014
Lactose degradation and galactose metabolism07
Biochemical pathways: part I0466

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency10.00000.003245.467312,589.2998AID2517
USP1 protein, partialHomo sapiens (human)Potency15.84890.031637.5844354.8130AID743255
IDH1Homo sapiens (human)Potency25.92900.005210.865235.4813AID686970
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
DNA polymerase kappa isoform 1Homo sapiens (human)Potency18.88760.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency7.07950.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain B, lectin I B chainViscum album (European mistletoe)IC50 (µMol)900.0000900.0000900.0000900.0000AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PA-I galactophilic lectinPseudomonas aeruginosa PAO1Kd87.50000.07100.07100.0710AID1884995
Chain A, L-ARABINOSE-BINDING PROTEINEscherichia coliKd0.01000.01000.01000.0100AID977611
Chain A, LectinErythrina corallodendronKd637.0000515.0000632.6667746.0000AID977611
Chain A, LectinErythrina corallodendronKd637.0000515.0000632.6667746.0000AID977611
Chain A, LectinErythrina corallodendronKd637.0000515.0000632.6667746.0000AID977611
Chain A, LectinErythrina corallodendronKd637.0000515.0000632.6667746.0000AID977611
Chain A, L-ARABINOSE-BINDING PROTEINEscherichia coliKd0.01000.01000.01000.0100AID977611
Chain A, GLUCOSE/GALACTOSE-BINDING PROTEINSalmonella enterica subsp. enterica serovar TyphimuriumKd0.20000.20000.20000.2000AID977611
Chain A, Agglutinin alpha chainArtocarpus integerKd820.0000820.0000820.0000820.0000AID977611
Chain A, Agglutinin alpha chainArtocarpus integerKd820.0000820.0000820.0000820.0000AID977611
Chain B, Agglutinin beta-3 chainArtocarpus integerKd820.0000820.0000820.0000820.0000AID977611
Chain A, Agglutinin alpha chainArtocarpus integerKd820.0000820.0000820.0000820.0000AID977611
Chain C, Agglutinin alpha chainArtocarpus integerKd820.0000820.0000820.0000820.0000AID977611
Chain D, Agglutinin beta-3 chainArtocarpus integerKd820.0000820.0000820.0000820.0000AID977611
Chain A, L-ARABINOSE-BINDING PROTEINEscherichia coliKd0.01000.01000.01000.0100AID977611
Chain A, L-ARABINOSE-BINDING PROTEINEscherichia coliKd0.23000.23000.23000.2300AID977611
Chain A, L-ARABINOSE-BINDING PROTEINEscherichia coliKd0.23000.23000.23000.2300AID977611
Chain A, L-ARABINOSE-BINDING PROTEINEscherichia coliKd0.01000.01000.01000.0100AID977611
Chain A, L-ARABINOSE-BINDING PROTEINEscherichia coliKd0.01000.01000.01000.0100AID977611
Chain A, L-ARABINOSE-BINDING PROTEINEscherichia coliKd0.01000.01000.01000.0100AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
carbohydrate metabolic processBeta-galactosidaseHomo sapiens (human)
galactose catabolic processBeta-galactosidaseHomo sapiens (human)
heparan sulfate proteoglycan catabolic processBeta-galactosidaseHomo sapiens (human)
keratan sulfate catabolic processBeta-galactosidaseHomo sapiens (human)
glycosphingolipid catabolic processBeta-galactosidaseHomo sapiens (human)
response to cortisoneBeta-galactosidaseHomo sapiens (human)
response to Thyroglobulin triiodothyronineBeta-galactosidaseHomo sapiens (human)
lipopolysaccharide core region biosynthetic processLipopolysaccharide heptosyltransferase 1Escherichia coli K-12
lipopolysaccharide biosynthetic processLipopolysaccharide heptosyltransferase 1Escherichia coli K-12
lipopolysaccharide core region biosynthetic processLipopolysaccharide heptosyltransferase 1Escherichia coli K-12
receptor-mediated endocytosisAsialoglycoprotein receptor 1Homo sapiens (human)
biological process involved in interspecies interaction between organismsAsialoglycoprotein receptor 1Homo sapiens (human)
positive regulation of dendritic cell differentiationGalectin-1Homo sapiens (human)
plasma cell differentiationGalectin-1Homo sapiens (human)
apoptotic processGalectin-1Homo sapiens (human)
T cell costimulationGalectin-1Homo sapiens (human)
regulation of apoptotic processGalectin-1Homo sapiens (human)
positive regulation of apoptotic processGalectin-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionGalectin-1Homo sapiens (human)
myoblast differentiationGalectin-1Homo sapiens (human)
positive regulation of viral entry into host cellGalectin-1Homo sapiens (human)
positive regulation of inflammatory responseGalectin-1Homo sapiens (human)
cell-cell adhesionGalectin-1Homo sapiens (human)
positive regulation of dendritic cell differentiationGalectin-3Homo sapiens (human)
monocyte chemotaxisGalectin-3Homo sapiens (human)
mRNA processingGalectin-3Homo sapiens (human)
RNA splicingGalectin-3Homo sapiens (human)
neutrophil chemotaxisGalectin-3Homo sapiens (human)
epithelial cell differentiationGalectin-3Homo sapiens (human)
positive regulation of protein-containing complex assemblyGalectin-3Homo sapiens (human)
regulation of T cell proliferationGalectin-3Homo sapiens (human)
innate immune responseGalectin-3Homo sapiens (human)
negative regulation of endocytosisGalectin-3Homo sapiens (human)
eosinophil chemotaxisGalectin-3Homo sapiens (human)
macrophage chemotaxisGalectin-3Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayGalectin-3Homo sapiens (human)
positive chemotaxisGalectin-3Homo sapiens (human)
regulation of T cell apoptotic processGalectin-3Homo sapiens (human)
mononuclear cell migrationGalectin-3Homo sapiens (human)
positive regulation of mononuclear cell migrationGalectin-3Homo sapiens (human)
positive regulation of calcium ion importGalectin-3Homo sapiens (human)
regulation of extrinsic apoptotic signaling pathway via death domain receptorsGalectin-3Homo sapiens (human)
positive regulation of protein localization to plasma membraneGalectin-3Homo sapiens (human)
negative regulation of protein tyrosine phosphatase activityGalectin-3Homo sapiens (human)
negative regulation of immunological synapse formationGalectin-3Homo sapiens (human)
negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cellGalectin-3Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayGalectin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
beta-galactosidase activityBeta-galactosidaseHomo sapiens (human)
protein bindingBeta-galactosidaseHomo sapiens (human)
galactoside bindingBeta-galactosidaseHomo sapiens (human)
protein homodimerization activityBeta-galactosidaseHomo sapiens (human)
protein bindingLipopolysaccharide heptosyltransferase 1Escherichia coli K-12
lipopolysaccharide heptosyltransferase activityLipopolysaccharide heptosyltransferase 1Escherichia coli K-12
glycosyltransferase activityLipopolysaccharide heptosyltransferase 1Escherichia coli K-12
ADP-heptose-lipopolysaccharide heptosyltransferase activityLipopolysaccharide heptosyltransferase 1Escherichia coli K-12
asialoglycoprotein receptor activityAsialoglycoprotein receptor 1Homo sapiens (human)
protein bindingAsialoglycoprotein receptor 1Homo sapiens (human)
identical protein bindingAsialoglycoprotein receptor 1Homo sapiens (human)
metal ion bindingAsialoglycoprotein receptor 1Homo sapiens (human)
fucose bindingAsialoglycoprotein receptor 1Homo sapiens (human)
mannose bindingAsialoglycoprotein receptor 1Homo sapiens (human)
RNA bindingGalectin-1Homo sapiens (human)
protein bindingGalectin-1Homo sapiens (human)
laminin bindingGalectin-1Homo sapiens (human)
lactose bindingGalectin-1Homo sapiens (human)
RNA bindingGalectin-3Homo sapiens (human)
protein phosphatase inhibitor activityGalectin-3Homo sapiens (human)
protein bindingGalectin-3Homo sapiens (human)
IgE bindingGalectin-3Homo sapiens (human)
protein phosphatase bindingGalectin-3Homo sapiens (human)
carbohydrate bindingGalectin-3Homo sapiens (human)
chemoattractant activityGalectin-3Homo sapiens (human)
laminin bindingGalectin-3Homo sapiens (human)
molecular condensate scaffold activityGalectin-3Homo sapiens (human)
disaccharide bindingGalectin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
extracellular regionBeta-galactosidaseHomo sapiens (human)
cytoplasmBeta-galactosidaseHomo sapiens (human)
Golgi apparatusBeta-galactosidaseHomo sapiens (human)
azurophil granule lumenBeta-galactosidaseHomo sapiens (human)
lysosomal lumenBeta-galactosidaseHomo sapiens (human)
intracellular membrane-bounded organelleBeta-galactosidaseHomo sapiens (human)
perinuclear region of cytoplasmBeta-galactosidaseHomo sapiens (human)
extracellular exosomeBeta-galactosidaseHomo sapiens (human)
ficolin-1-rich granule lumenBeta-galactosidaseHomo sapiens (human)
vacuoleBeta-galactosidaseHomo sapiens (human)
plasma membraneLipopolysaccharide heptosyltransferase 1Escherichia coli K-12
cytosolLipopolysaccharide heptosyltransferase 1Escherichia coli K-12
extracellular regionAsialoglycoprotein receptor 1Homo sapiens (human)
plasma membraneAsialoglycoprotein receptor 1Homo sapiens (human)
external side of plasma membraneAsialoglycoprotein receptor 1Homo sapiens (human)
collagen-containing extracellular matrixGalectin-1Homo sapiens (human)
extracellular regionGalectin-1Homo sapiens (human)
extracellular spaceGalectin-1Homo sapiens (human)
cytoplasmGalectin-1Homo sapiens (human)
endoplasmic reticulum lumenGalectin-1Homo sapiens (human)
cytosolGalectin-1Homo sapiens (human)
collagen-containing extracellular matrixGalectin-1Homo sapiens (human)
extracellular exosomeGalectin-1Homo sapiens (human)
galectin complexGalectin-1Homo sapiens (human)
extracellular spaceGalectin-1Homo sapiens (human)
collagen-containing extracellular matrixGalectin-3Homo sapiens (human)
immunological synapseGalectin-3Homo sapiens (human)
extracellular regionGalectin-3Homo sapiens (human)
extracellular spaceGalectin-3Homo sapiens (human)
nucleusGalectin-3Homo sapiens (human)
nucleoplasmGalectin-3Homo sapiens (human)
cytoplasmGalectin-3Homo sapiens (human)
mitochondrial inner membraneGalectin-3Homo sapiens (human)
cytosolGalectin-3Homo sapiens (human)
plasma membraneGalectin-3Homo sapiens (human)
cell surfaceGalectin-3Homo sapiens (human)
membraneGalectin-3Homo sapiens (human)
secretory granule membraneGalectin-3Homo sapiens (human)
collagen-containing extracellular matrixGalectin-3Homo sapiens (human)
extracellular exosomeGalectin-3Homo sapiens (human)
ficolin-1-rich granule membraneGalectin-3Homo sapiens (human)
spliceosomal complexGalectin-3Homo sapiens (human)
cytoplasmGalectin-3Homo sapiens (human)
immunological synapseGalectin-3Homo sapiens (human)
nucleusGalectin-3Homo sapiens (human)
extracellular spaceGalectin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (84)

Assay IDTitleYearJournalArticle
AID1802833β-Gal Inhibitory Assay from Article 10.1074/jbc.M113.529529: \\Structural basis of pharmacological chaperoning for human u00DF-galactosidase.\\2014The Journal of biological chemistry, May-23, Volume: 289, Issue:21
Structural basis of pharmacological chaperoning for human β-galactosidase.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1373944Inhibition of Escherichia coli Heptosyltransferase I assessed as reduction in ADP release using ODLA and ADP-heptose substrates in presence of phospho(enol)pyruvate and NADH by pyruvate kinase and LDH based ADP/NADH coupling assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Synthesis, kinetics and inhibition of Escherichia coli Heptosyltransferase I by monosaccharide analogues of Lipid A.
AID202220Percentage uptake of 5 mM 6-F-galactose into macromolecule of human mammary tumor cells was measured in the presence of radiolabeled [3H]galactose, as cpm/ug of protein1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Halogenated L-fucose and D-galactose analogues: synthesis and metabolic effects.
AID238137Dissociation constant against galectin-3 using competitive fluorescence polarization2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis of O-galactosyl aldoximes as potent LacNAc-mimetic galectin-3 inhibitors.
AID381594Anticryptosporidial activity against Cryptosporidium hominis TU502 assessed as inhibition of rabbit erythrocytes hemagglutinination2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID381597Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells relative to galactose2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID381595Anticryptosporidial activity against Cryptosporidium hominis TU502 assessed as inhibition of rabbit erythrocytes hemagglutinination relative to galactose2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID731591Induction of beta glucosidase N370S mutant activity in primary skin fibroblasts derived from Gaucher disease type 1 patient at 10 to 20 mM after 7 days relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID500279Ratio of Kcat to Km for Neisseria meningitidis lgtC2006Nature chemical biology, Dec, Volume: 2, Issue:12
Using substrate engineering to harness enzymatic promiscuity and expand biological catalysis.
AID202217Percentage incorporation of 5 mM 6-F-galactose into macromolecule of human mammary tumor cells was measured in the presence of radiolabeled [3H]galactose, as cpm/microg of protein1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Halogenated L-fucose and D-galactose analogues: synthesis and metabolic effects.
AID1626713Inhibition of CFTR in human intestinal organoids assessed as reduction in forskolin-induced oganoids swelling incubated for 4 hrs with cholera toxin followed by subsequent stimulation with 0.1 uM forskolin by calcein AM staining based confocal microscopy2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Functional Characterization of Cholera Toxin Inhibitors Using Human Intestinal Organoids.
AID1524938Binding affinity to jackfruit jacalin by SPR assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Modulation of the NOD-like receptors NOD1 and NOD2: A chemist's perspective.
AID1626711Inhibition of HRP-tagged Vibrio cholerae cholera enterotoxin subunit B5 binding to GM1 coated plates using GM1os-beta-NAc-propargyl2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Functional Characterization of Cholera Toxin Inhibitors Using Human Intestinal Organoids.
AID731590Induction of beta galactosidase R401H mutant activity in fibroblasts derived from patient relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID381596Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID1373942Substrate activity at Escherichia coli Heptosyltransferase I assessed as ADP release at 100 uM using phospho(enol)pyruvate and NADH by pyruvate kinase and LDH based ADP/NADH coupling assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Synthesis, kinetics and inhibition of Escherichia coli Heptosyltransferase I by monosaccharide analogues of Lipid A.
AID1373943Inhibition of Escherichia coli Heptosyltransferase I assessed as reduction in ADP release at 1 mM using ODLA and ADP-heptose substrates in presence of phospho(enol)pyruvate and NADH by pyruvate kinase and LDH based ADP/NADH coupling assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Synthesis, kinetics and inhibition of Escherichia coli Heptosyltransferase I by monosaccharide analogues of Lipid A.
AID381593Anticryptosporidial activity against Cryptosporidium parvum GCH1 assessed as inhibition of rabbit erythrocytes hemagglutinination relative to galactose2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID381592Anticryptosporidial activity against Cryptosporidium parvum GCH1 assessed as inhibition of rabbit erythrocytes hemagglutinination2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID1626712Inhibition of cholera toxin in human intestinal organoids assessed as reduction in oganoids swelling using cholera toxin pre-incubated with compound for 4 hrs before organoid stimulation with cholera toxin by calcein AM staining based confocal microscopy2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Functional Characterization of Cholera Toxin Inhibitors Using Human Intestinal Organoids.
AID1884995Binding affinity to Pseudomonas aeruginosa PAO1 LecA expressed in Escherichia coli assessed as dissociation constant by isothermal titration calorimetry2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Small Carbohydrate Derivatives as Potent Antibiofilm Agents.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1993Journal of molecular biology, Oct-20, Volume: 233, Issue:4
The 1.7 A refined X-ray structure of the periplasmic glucose/galactose receptor from Salmonella typhimurium.
AID1811Experimentally measured binding affinity data derived from PDB1993Journal of molecular biology, Oct-20, Volume: 233, Issue:4
The 1.7 A refined X-ray structure of the periplasmic glucose/galactose receptor from Salmonella typhimurium.
AID452769Binding affinity to human recombinant ASGPR1 carbohydrate recognition domain expressed in Escherichia coli AD494 by surface plasmon resonance spectroscopy relative to D-GalNAc2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R).
AID305308Inhibition of carbohydrate-dependent human galectin3 binding at 10 mM by solid phase assay2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries.
AID38895Binding affinity against Arabinose binding protein of the compound2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID452767Inhibition of D-GalNAc-PAA binding to human recombinant ASGPR1 carbohydrate recognition domain expressed in Escherichia coli AD494 by competitive solid-phase binding assay relative to D-GalNAc2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R).
AID35662Binding affinity against Amiloride-sensitive amine oxidase [ABP(P254G)]2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID35661Binding affinity against Amiloride-sensitive amine oxidase [ABP(M108L)]2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID452766Inhibition of D-GalNAc-PAA binding to human recombinant ASGPR1 carbohydrate recognition domain expressed in Escherichia coli AD494 by competitive solid-phase binding assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R).
AID30427Compound was tested for inhibition of Human acrosin by aldohexoses1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Inhibition of human acrosin by monosaccharides and related compounds: structure-activity relationships.
AID452771Inhibition of [125I]asialoorosomucoid binding to rabbit hepatic ASGPR1 relative to D-GalNAc2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R).
AID452768Binding affinity to human recombinant ASGPR1 carbohydrate recognition domain expressed in Escherichia coli AD494 by surface plasmon resonance spectroscopy2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R).
AID305307Inhibition of carbohydrate-dependent human galectin1 binding at 10 mM by solid phase assay2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries.
AID452770Inhibition of [125I]asialoorosomucoid binding to rabbit hepatic ASGPR12009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R).
AID238137Dissociation constant against galectin-3 using competitive fluorescence polarization2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis of O-galactosyl aldoximes as potent LacNAc-mimetic galectin-3 inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB1998Journal of molecular biology, Apr-10, Volume: 277, Issue:4
Structures of the Erythrina corallodendron lectin and of its complexes with mono- and disaccharides.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1998Journal of molecular biology, Apr-10, Volume: 277, Issue:4
Structures of the Erythrina corallodendron lectin and of its complexes with mono- and disaccharides.
AID1811Experimentally measured binding affinity data derived from PDB1990The Journal of biological chemistry, Sep-25, Volume: 265, Issue:27
A Pro to Gly mutation in the hinge of the arabinose-binding protein enhances binding and alters specificity. Sugar-binding and crystallographic studies.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1990The Journal of biological chemistry, Sep-25, Volume: 265, Issue:27
A Pro to Gly mutation in the hinge of the arabinose-binding protein enhances binding and alters specificity. Sugar-binding and crystallographic studies.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2005Acta crystallographica. Section F, Structural biology and crystallization communications, Jan-01, Volume: 61, Issue:Pt 1
Mistletoe lectin I in complex with galactose and lactose reveals distinct sugar-binding properties.
AID1811Experimentally measured binding affinity data derived from PDB2005Acta crystallographica. Section F, Structural biology and crystallization communications, Jan-01, Volume: 61, Issue:Pt 1
Mistletoe lectin I in complex with galactose and lactose reveals distinct sugar-binding properties.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2003Journal of molecular biology, Sep-05, Volume: 332, Issue:1
Structural basis of the carbohydrate specificities of jacalin: an X-ray and modeling study.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID261924Inhibition of Galectin12006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Aryl O- and S-galactosides and lactosides as specific inhibitors of human galectins-1 and -3: role of electrostatic potential at O-3.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID362218Inhibition of recombinant galectin 1 in human O type red blood cells by hemagglutinination assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Synthesis of stable and selective inhibitors of human galectins-1 and -3.
AID30432Compound was tested for inhibition of Human acrosin by phosphorylated monosaccharides1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Inhibition of human acrosin by monosaccharides and related compounds: structure-activity relationships.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID261925Inhibition of Galectin32006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Aryl O- and S-galactosides and lactosides as specific inhibitors of human galectins-1 and -3: role of electrostatic potential at O-3.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID362221Inhibition of recombinant galectin 3 in human O type red blood cells by hemagglutinination assay relative to galactose2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Synthesis of stable and selective inhibitors of human galectins-1 and -3.
AID362219Inhibition of recombinant galectin 3 in human O type red blood cells by hemagglutinination assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Synthesis of stable and selective inhibitors of human galectins-1 and -3.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID71736Inhibitory concentration against Escherichia coli heat-labile enterotoxin (LT) binding to ganglioside GD1b was determined by ELISA assay1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
The role of waters in docking strategies with incremental flexibility for carbohydrate derivatives: heat-labile enterotoxin, a multivalent test case.
AID1453085Inhibition of lectin in C57BL/6 mouse kidney using SK-5100 as substrate incubated for 30 mins by VAA staining based microscopic analysis2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Bivalent O-glycoside mimetics with S/disulfide/Se substitutions and aromatic core: Synthesis, molecular modeling and inhibitory activity on biomedically relevant lectins in assays of increasing physiological relevance.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID51624Affinity towards Cholera toxin B5 pentamer2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
Second generation mimics of ganglioside GM1 as artificial receptors for cholera toxin: replacement of the sialic acid moiety.
AID362220Inhibition of recombinant galectin 1 in human O type red blood cells by hemagglutinination assay relative to galactose2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Synthesis of stable and selective inhibitors of human galectins-1 and -3.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1989Nature, Aug-03, Volume: 340, Issue:6232
Substrate specificity and affinity of a protein modulated by bound water molecules.
AID1811Experimentally measured binding affinity data derived from PDB1989Nature, Aug-03, Volume: 340, Issue:6232
Substrate specificity and affinity of a protein modulated by bound water molecules.
AID1811Experimentally measured binding affinity data derived from PDB1991Biochemistry, Jul-16, Volume: 30, Issue:28
Sugar-binding and crystallographic studies of an arabinose-binding protein mutant (Met108Leu) that exhibits enhanced affinity and altered specificity.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1991Biochemistry, Jul-16, Volume: 30, Issue:28
Sugar-binding and crystallographic studies of an arabinose-binding protein mutant (Met108Leu) that exhibits enhanced affinity and altered specificity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24,249)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012429 (51.26)18.7374
1990's2752 (11.35)18.2507
2000's3308 (13.64)29.6817
2010's4225 (17.42)24.3611
2020's1535 (6.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 78.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index78.22 (24.57)
Research Supply Index9.86 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index164.81 (26.88)
Search Engine Supply Index2.26 (0.95)

This Compound (78.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials193 (1.02%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Trials44 (0.65%)5.53%
Reviews689 (3.63%)6.00%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Reviews249 (3.70%)6.00%
Case Studies286 (1.51%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies38 (0.57%)4.05%
Observational17 (0.09%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational2 (0.03%)0.25%
Other17,803 (93.76%)84.16%
Other10 (100.00%)84.16%
Other9 (100.00%)84.16%
Other6,388 (95.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]